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ANXA1 is an immune-modulatory protein and is known to play important role 
in cell differentiation, adhesion, migration, proliferation and apoptosis. Our lab 
has already shown its involvement in TLR3 signalling. To follow up this study 
with the other RNA sensing receptors we chose to investigate the effects of 
ANXA1 in TLR7 signalling by using an artificial agonist, R848 and a natural 
ligand Influenza virus. In this project, cytokine production in various cell types 
with TLR7 agonist R848 was observed which indicated the cell-specificity 
exhibited by ANXA1, due to which bone marrow macrophages require 
ANXA1 for cytokine production while bone marrow dendritic cells can 
produce high amounts of cytokines in its absence. We also established that 
ANXA1 plays a role in Influenza virus infection and positively regulates virus 
titers due to which ANXA1-/- mice have greater survival rates compared to 
WT. No differences are observed in cytokine levels or lung damage. Invitro 
analysis of viral titers in human alveolar type II epithelial cell line A549, show 
similar results as observed in vivo. Overexpression of ANXA1 leads to higher 
viral loads whereas the knockdown reduces viral loads. Apoptosis favours viral 
propagation and hence higher apoptosis may lead to higher viral loads in the 
lungs of infected mice.  In all, our study shows that ANXA1 plays a 
detrimental role in the influenza infection and better targeting of the molecule 
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Chapter 1 Introduction 
 
1.1.  Annexin 1 
 
Annexin 1 (ANXA1) is the first characterized member of the annexin 
superfamily which comprises of 13 calcium or phospholipid binding proteins. 
It is a 37kDa protein and was identified as an inhibitory protein that mimics the 
inhibitory action of glucocorticoids (Flower, 1988). Since the time of its 
discovery in late 1970s it has changed various names from macrocortin 
(Blackwell et al., 1980) to renocortin (Rothhut, Russo-Marie, Wood, DiRosa, 
& Flower, 1983), lipomodulin (Hirata et al., 1981), lipocortin-1 and finally 
ANXA1 since ANXA1 encoding gene is located on chromosome 19q24 (Lim 
& Pervaiz, 2007). 
1.1.1. Structure of ANXA1 
 
The annexins are ubiquitous and are found throughout the animal and plant 
kingdom. The structure comprises of tightly packed core domain made of α-
helices. The center of the core is hydrophilic so as to function as a Ca2+ 
channel. The C terminal of Annexins is highly conserved but N terminal is 
unique for a given member. The N terminus is the regulatory region and 
contains the sites for phophorylation and proteolysis (Raynal & Pollard, 1994). 
Annexins must be able to bind the negatively charged phospholipids in a 
calcium dependant manner. All Annexins except Annexin 6 have a core 
domain containing four repeating units comprising of approximately 70 amino 
acids. The binding is reversible and removal of calcium leads to the disruption 
21
of interactions between annexins and phospholipids (Gerke & Moss, 2002). 
The crystal structure of ANXA1 consisting of 346 amino acids is described as 
a “doughnut”. The N-terminal remains hidden in the pore at low Ca2+ 
concentrations but an increase in the Ca2+ concentration exposes this region 
thereby influencing its biological activity (Rosengarth, Gerke, & Luecke, 2001; 
Rosengarth, Rosgen, Hinz, & Gerke, 2001). 
 
 
Figure 1.1 Schematic representation of ANXA1 protein 
The N terminal is the biologically active part while the four repeats represent 
the conserved C-terminal domain (adapted from Atlas of Genetics and 
Cytogenetics in Oncology and Haematology). 
 
1.1.2. Functions of ANXA1 
 
ANXA1 is mainly identified as an anti-inflammatory protein that mimics the 
effects of glucocorticoids. Its reactions with various inflammatory mediators to 
control inflammation are described below. 
1.1.2.1. Interaction with Phopholipase -2 (PLA2) 
 
ANXA1 was originally identified as the PLA2 inhibitor. There are two 
isoforms of PLA2 namely cytosolic PLA-2 (cPLA2) and secretory PLA2 
(sPLA2). cPLA2 is highly specific for the release of arachidonic acid from the 
sn2 position of phospholipids (Mukherjee, Miele, & Pattabiraman, 1994). The 
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second carbon of the glycerol molecule in phospholipids is described as the sn2 
position. The direct interaction between cPLA2 and ANXA1 was determined 
by immunoprecipitation and mammalian two hybrid studies. cPLA2 activity 
was inhibited by both the full length and C-terminal region but not by the N-
terminal protein (S. W. Kim et al., 2001). The enzyme kinetic studies done by 
measuring the degree of inhibition at various substrate and calcium 
concentrations revealed that the inhibition is a function of the enzyme activity 
and is independent of substrate concentration (K. M. Kim, Kim, Park, Kim, & 
Na, 1994) . However, this interaction between ANXA1 and cPLA2 is cell type 
specific. A clearer picture of the functional link between these two has been 
shown in hepatocytic cell lines (de Coupade et al., 2000).  
 
1.1.2.2.  Mediation of Glucocorticoid (GC) Actions 
 
ANXA1 mediates the anti-inflammatory reactions of GCs was revealed when  
cyclooxygenase 2 (COX-2) mRNA and protein levels were constitutively 
increased in ANXA1-/- mice and GCs were ineffective in bringing out any 
effects in these mice (Hannon et al., 2003). ANXA1 can be induced by GCs 
and is rapidly mobilized and secreted by target cells to mimic their anti-
inflammatory effects (J. D. Croxtall, van Hal, Choudhury, Gilroy, & Flower, 
2002; McLeod, Goodall, Jelic, & Bolton, 1995; Peers, Smillie, Elderfield, & 
Flower, 1993; Solito, Nuti, & Parente, 1994). GCs can also induce the 
phosphorylation and translocation of ANXA1 to membrane via protein kinase 
C (PKC), Phosphatidylinositide 3-kinases (PI3K) and Mitogen-activated 
protein kinases (MAPK) dependent pathways (Solito, Mulla, et al., 2003). In 
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rheumatoid arthritis ANXA1 was found to be present in arthritic synovium and 
mediated the effects of GCs on the migration of neutrophils in carrageenan 
induced acute arthritis. The condition aggravated on injection of anti-ANXA1 
antibodies and neutrophil activation was inhibited (Y. Yang, Leech, 
Hutchinson, Holdsworth, & Morand, 1997). 
 
1.1.2.3.  Proliferation and Apoptosis 
 
The role of ANXA1 in proliferation and apoptosis is still unclear. Opposing 
phenotypes have been observed based on cell types. ANXA1 is shown to be 
anti-proliferative in case of A549 lung cancer cells (J. Croxtall, Flower, & 
Perretti, 1993) and macrophages. ANXA1 is believed to exert this anti-
proliferative property in macrophages by being phophorylated by epidermal 
growth factor (EGF) and hence keeping MAPK/ERK pathway constitutively 
active (Alldridge, Harris, Plevin, Hannon, & Bryant, 1999). It can bind to Grb-
2 adaptor protein, which is upstream of MAPK pathway and bring about 
disruption of actin cytoskeleton and inhibition of cyclin D1 (Alldridge & 
Bryant, 2003). ANXA1 acts like a substrate or target for various signal 
transducing kinases associated with platelet-derieved growth factor (PDGF) 
receptor, hepatocyte growth factor receptor (Skouteris & Schroder, 1996) , 
protein kinase C (Varticovski et al., 1988) and TRPM7 channel kinase 
(Dorovkov & Ryazanov, 2004) thus being an important player in proliferation. 
All the above mentioned data places ANXA1 as an anti-proliferative protein; 
however in hepatocytes its role is completely reversed. Its phosphorylation by 
hepatocyte growth factor leads to it acting as a signal amplifier to enhance 
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proliferation, chemotaxis and differentiation (Skouteris & Schroder, 1996) 
ANXA1 also sigmals mitogen-stimulated breast tumour cell proliferation by 
activation of frormyl peptide receptors 1&2 (Khau et al.,2010). 
 
The cell-dependant differences shown by ANXA1 in proliferation are also 
exhibited in apoptosis. It is believed that ANXA1 mediates the proapoptotic 
effects of glucocorticoids. The involvement of ANXA 1 in apoptosis was first 
in alveolar cells of mammary duct (McKanna, 1995). Following this 
observation a few more papers discussed the role of ANXA 1 in the induction 
of apoptosis. ANXA1 is shown to facilitate H2O2 induced apoptosis 
(Sakamoto, Repasky, Uchida, Hirata, & Hirata, 1996), promotes caspase-3 
activation (Solito, de Coupade, Canaider, Goulding, & Perretti, 2001) and 
stimulate transient increase in the intracellular calcium concentrations (Solito, 
Kamal, et al., 2003). It also induces apoptosis in neutrophils by intracellular 
release of calcium which leads to dephorphorylation of Bcl-2 associated death 
promoter (BAD) allowing it to associate with mitochondria (Solito, Kamal, et 
al., 2003). Apart from the effects on caspase 3 activation and increase in 
calcium concentrations other proposed mechanisms of action for ANXA1 are 
inhibition of eicosanoid (Goetzl, An, & Zeng, 1995) and nitric oxide synthesis 
(Genaro, Hortelano, Alvarez, Martinez, & Bosca, 1995).  
 
1.1.2.4.  Annexin 1 Null mouse 
 
The availability of mice lacking ANXA 1 has given a boost to the research in 
this area. It was generated by disruption of ANXA1 gene by homologous 
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recombination with lacZ gene. COX-2 and PLA2 expressions are up regulated 
in lungs and thymus. Annexins 2, 4 and 6 are downregulated in ovary and liver 
and upregulated in a few other organs like stomach, kidney and spleen 
(Hannon, et al., 2003) Annexin 1 knockout mice exhibited responses like 
increase in leukocyte transmigration (Chatterjee et al., 2005), delayed repair in 
colitis (Babbin et al., 2008) and partial resistance to dexamethasone (Hannon, 
et al., 2003). 
 
1.1.2.5.  Pro-inflammatory actions 
 
ANXA1 is widely accepted as an anti-inflammatory protein but a few recent 
studies have indicated that it can act opposite of its usual role upon cleavage. 
The 3kDa cleavage product of ANXA1 is shown to promote neutrophil 
transmigration via its effects on endothelial intracellular adhesion molecule 1 
(ICAM-1) (Williams et al., 2010) and leukocyte chemotaxis via formyl peptide 
receptor (FPR) family members (Ernst et al., 2004). ANXA1 is also secreted 
from the rheumatoid arthiritis synovial fibriblasts (RASF) following Tumour 
necrosis factor (TNF)-mediated activation to promote RASF matrix 
metellaproteinase -1 secretion (Tagoe et al., 2008). The pro-inflammatory 
effects can also be observed in the increased phosphorylation of PLA2 and 
eicosanoid production in mast cells (Kwon et al., 2012, Chung et al., 2004). 
 
1.1.2.6.  Phagocytosis “EAT me” signals 
 
Specific ‘eat me’ signals on the apoptotic cells serve as markers for phagocytes 
so that they can recognize and ingest the apoptotic cells. One of the 
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characteristics of apoptotic cells is the exposure of phophotidyl serine (PS) on 
the outer leaflet of plasma membrane (Lim & Pervaiz, 2007). PS dependant 
clearance of cells inhibits the release of pro inflammatory cytokines like 
interleukin-1β (IL-1β) and TNF-α but stimulates the release of anti-
inflammatory cytokines like transforming growth factor (TGF-β). It is 
suggested that ANXA1 might be an endogenous ligand facilitating the 
clearance of apoptotic cells in a caspase or calcium dependant manner by 
carrying out experiments where ANXA 1 gene has been silenced and a 
defective engulfment of apoptotic cells was observed (Arur et al., 2003). 
Monoclonal antibodies to ANXA1 have been shown to inhibit PS dependant 
phagocytosis in lymphocytes (Fan, Krahling, Smith, Williamson, & Schlegel, 
2004). The PS molecules are present on both phagocytes and apoptotic cells 
whereas the PS receptor is present only on the surface of phagocytic cells. It 
nay therefore be reasoned that ANXA 1 might act like a receptor to recognize 

















Figure 1.2 The diverse biological actions of ANXA1 
A) ANXA1 was found to inhibit the activity of cytosolic phospholipase A2 
(cPLA2) and cyclooxygenase 2 (COX-2), thus exhibiting antiinflammatory, 
antipyretic, and antihyperalgesic activity. B) Exogenous ANXA1 acts on its 
receptor, recently identified as the formyl peptide receptor (FPR) and the 
formyl peptide receptor like-1 (FPRL1) to inhibit cell adhesion and migration, 
and induce detachment of adherent cells. When cells (particularly neutrophils) 
adhere onto the endothelium, ANXA1 is released together with the gelatinase 
granules and can act like exogenous ANXA1. C) ANXA1 expression can be 
up-regulated with GC treatment through the glucocorticoid receptor (GR), 
which contributes to its antiinflammatory activity. GCs can also induce rapid 
ANXA1 phosphorylation and membrane translocation. D) ANXA1 is recruited 
to the cell surface, where it binds to PS and mediates the engulfment of 
apoptotic cells. E) ANXA1 can be phosphorylated by a number of kinases, 
including EGF-R tyrosine kinase, protein kinase C (PKC), platelet-derived 
growth factor receptor tyrosine kinase (PDGFR-TK), and hepatocyte growth 
factor receptor tyrosine kinase (HGFR-TK) to mediate proliferation. F) 
Overexpression of ANXA1 induces apoptosis. ANXA1 can mediate apoptosis 
by inducing the dephosphorylation of BAD, allowing BAD to translocate to the 
mitochondria. During apoptosis, ANXA1 itself translocates to the nucleus, 




1.1.3. The ANXA1 receptor 
 
Formyl peptide receptor 2 (FPR2) (or ALXR in humans) is a G-protein coupled 
receptor (GPCR) through which ANXA1 signals (Perretti et al., 2002). It 
belongs to a family of three receptors FPR1, ALXR/FPR2 and FPR3 which are 
expressed by several cell types like monocytes, neutrophils, epithelial cells, 
endothelial cells and macrophages (Babbin et al., 2006; Chiang et al., 2006). 
The interaction between ANXA1 and its receptor was investigated by 
immunoprecipitating ANXA1 from neutrophils with FPR2 when the 
leukocytes were adhered to endothelium monolayers (Solito, Kamal, et al., 
2003). FPR2 is also the receptor for another anti-inflammatory molecule 
lipoxin A4 (Perretti & D'Acquisto, 2009). Binding of ANXA1 to its receptor 
leads to the transient phosphorylation of extracellular–regulated kinase 1 and 2 
(ERK-1and ERK-2) (Hayhoe et al., 2006; He, Shepard, Chen, Pan, & Ye, 
2006) followed by rapid increase in the levels of intracellular Ca2+ (Babbin, et 
al., 2006; Solito, Kamal, et al., 2003). Blocking the receptor with monoclonal 
antibodies prevented ANXA1 induced effects on neutrophil transmigration 
(Babbin, et al., 2006).  
 
1.1.4. ANXA1 and APCs 
 
Dendritic cells (DC) and macrophages are the key APCs that connect innate 
and adaptive immunity. ANXA1 plays a major role DC maturation. ANXA1-/- 
BMDCs acquire a mature phenotype during differentiation and lose their 
antigen uptake capacity compared to wild-type BMDCs (Huggins, Paschalidis, 
Flower, Perretti, & D'Acquisto, 2009). This observation is supported by 
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another study where lack of DC maturation in presence of ANXA1 suppresses 
T cell immunity (Weyd et al., 2013). ANXA1 is expressed by different tissue-
specific macrophages such as alveolar (Ambrose et al., 1992), peritoneal (Peers 
et al., 1993), synovial (Yang et al., 1998) and microglial cells (Minghetti et al., 
1999) It exhibits a wide variety of roles in these cells such as proliferation 
(Alldridge et al., 1999), cytokine production (Y. H. Yang et al., 2006) and 
phagocytosis (Yona et al., 2006) making it an important molecule in the cell 
functioning. The activation of these APCs is through the cell surface receptors 
one of which are toll like receptors which we will discuss in next section. 
 
1.2. Toll like Receptors (TLRs) 
 
TLRS are type 1 transmembrane proteins that detect Pathogen Associated 
molecular patterns (PAMPS). They were first identified in drosophila.  They 
comprise of leucine rich repeats that sense the incoming PAMP and 
intracellular Toll-interleukin 1 receptor (TIR) domain that initiates the 
downstream signalling. There are 13 TLRs known so far and each one 
recognizes a specific PAMP. All TLRs and their ligands are given in the table 
below (Table 1.1).  
 
Receptor Ligand(PAMPs) Origin of Ligand 
TLR1 Triacyllipopeptides 
Soluble factors 
Bacteria and mycobacteria 
Neisseria meningitidis 
TLR2 Heat Shock protein 70 
Peptidogycan 
Lipoprotein 
HCV core and NS3 protein
Host 
Gram-positive bacteria 
Hepatitis C virus 







Mouse mammary-tumour virus 
Plants 







TLR7 ssRNA Viruses 
TLR8 ssRNA Viruses 
TLR9 CpG-containing DNA Bacteria 
Plasmodium 
Viruses 
TLR10 Not determined Not determined 
TLR11 Profillin-like molecule Taxoplasma gondii 
Table 1.1 TLRs and their ligands 
 
TLRs 1, 2,4,5,6 and 11 are localised on the plasma membrane and mainly 
recognize microbial membrane components such as lipids and proteins whereas 
TLRs 3, 7, 8 and 9 are expressed in intracellular vesicles such as endosomes, 
lysosomes and endolysosomes where they recognize the microbial nucleic 
acids. TLRs require TIR-domain containing adapters to trigger the downstream 
signalling pathways. These adapters are MyD88, Mal, TIR-domain-containing 
adapter-inducing interferon-β (TRIF)  and  TRIF-related adaptor molecule 
(TRAM). Each TLR uses one or combination of these adapters which in turn 
determines the signalling pathway to be activated. The first discovered adapter, 
MyD88 is used by all TLRs except TLR3 to activate NF-κB and MAPKs for 
the induction of pro-inflammatory cytokines. TLRs 3 and 4 use TRIF to 
activate IRFs and NF- κB for the induction of pro-inflammatory cytokines and 
type I interferons. TRAM and Mal act as bridges to recruit TRIF to TLR4 and 
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MyD88 to TLR2 and 4. Therefore, TLR signalling can be classified to MYD88 
dependent or TRIF dependent pathways. TLR4 is the only receptor that uses all 
four adapter molecules (Kawai and Akira, 2011). 
1.2.1.  MyD88 dependent pathway  
 
Upon activation of TLRs via MyD88 dependent pathway IL-1 receptor 
associated kinase-4 (IRAK-4) is stimulated, which then mediates the activation 
of IRAK-1 and IRAK-2. Activated IRAK-1 then interacts with Tumor necrosis 
factor receptor-associated factor-6 (TRAF-6) which is an E3 ubiquitin ligase 
and catalyzes the synthesis of polyubiquitin chains linked to Lys63. This 
activates Transforming Growth Factor β-activated Kinase 1 (TAK1) complex 
which simultaneously leads to the activation of two downstream pathways. The 
first one results in the activation of activator protein 1 (AP-1) through MAPKs 
and the second one activates NF-κB through IκB kinase β (IKKβ) which 
phosphorylates IκB thus leading to its degradation and translocation of NF-κB 
to the nucleus (Akira & Takeda, 2004; Kawai & Akira, 2010). The intracellular 
TLRs 3, 7 and 9 also depend on MyD88-IRAK-TRAF6 for downstream 
signalling and activate IRFs mainly IRF7. The above mentioned complex 
interacts with IRF7 causing its phosphorylation and translocation to the nucleus 
(Honda et al., 2004). 
1.2.2. TRIF-dependent pathway 
 
TRIF dependent pathway culminates in the activation of both IRF3 and NF-κB. 
TRAF6 is recruited to the N-terminus of TRIF for the activation of NF-κB in a 
mechanism similar to that of MyD88 dependent pathway. In addition to this 
RIP1 is recruited to the C terminus for the formation of the multiprotein 
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complex comprising of TRIF, TRAF6 and RIP-1 thus activating TAK 1 and 
NF-κB (L. A. O'Neill & Bowie, 2007). For the activation of IRF3 and IFN-β 
transcription TRIF activates the non-cannonical kinases IKKε and TBK-1 
through TRAF3. These kinases phosphorylate IRF-3 and drive its translocation 
to the nucleus (H. Hacker & Karin, 2006). 
1.2.3. Intracellular TLRs 
 
TLRs 3, 7, 8 and 9 are the intracellular TLRs that recognize the nucleic acids 
from microbial origin. Since Influenza is a ssRNA virus and forms a dsRNA 
intermediate during replication TLRs 3 and 7 play a major role in its 
recognition and activation of downstream signalling. They are localized in ER 
in the unstimulated cells and rapidly translocate to the endolysosomes upon 
stimulation (Y. M. Kim, Brinkmann, Paquet, & Ploegh, 2008). TLR 3 
recognizes double stranded (ds) RNA or its synthetic analog polyionosinic-
polycytidylic acid (poly (I: C)), which mimics viral infection and induces the 
production of both pro-inflammatory cytokines and Type I interferons (Akira, 
Uematsu, & Takeuchi, 2006). Single stranded (ss) RNA , imidazoquinoline 
derivatives and guanine analogs are the ligands for TLR7 (Kawai & Akira, 
2006). TLR7 is highly expressed on plasmacytoid dendritic cells (pDCs) that 
are able to produce large amounts of type I interferons during a viral infection. 
Viruses are internalized and fused to the endolysosomes where TLR7 
recognizes ssRNA and antiviral responses are triggered. TLR7 on cDCs also 
recognize RNA from bacterial species like Streptococcus and induce type I 
interferons (Mancuso et al., 2009). TLR8 is homologous to TLR7. Human 
TLR8 also recognizes ssRNA and imidazoquinolines. It is not functional in 
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mice and is expressed on various cells types, the highest expression being on 
monocytes. TLR9 recognizes unmethylated 2’-deoxyribo (cytidine-phosphate 
guanosine) (CpG) that are present in microbes but uncommon in mammalian 
cells. TLR9 ligands activate DCs, macrophages and B cells and drive strong 
TH1 responses (Akira, et al., 2006).  
 
 
Figure 1.3 TLR signalling pathway 
TLR signalling begins with recognition of the ligands by TLR receptors. The 
adaptor, Myd88 associates with TLRs and recruits IRAK. IRAK then activates 
IKK complex to phosphorylate IκB, resulting in the translocation of NF-κB to 
the nucleus which induces expression of pro-inflammatory cytokines. TIRAP is 
another adaptor involved in TLR 2 and 4 signalling.TLR3 and 4 signal through 
TRIF in a MyD88-independent manner, leading to the activation of IRF-3 and 
production of IFN-β. Non-cannonical IKKs, IKKi and TBK-1 also activate 
IRF-3. Another adaptor TRAM is specific to MyD88 independent TLR4 







1.2.4. ANXA1 and TLRs 
 
As discussed above TLR signaling pathways culminates in the activation of 
MAPKs, NF-κB or IRFs. It has been shown that ANXA1 regulates the 
activation of ERK1/2 in response to LPS (Alldridge & Bryant, 2003). ANXA1 
also regulates the expression of IL-6 by affecting p38 MAPK and MAPK 
phosphatase-1(Y. H. Yang, et al., 2006). GCs have also been shown to interfere 
with IRF-3 phosphorylation and promoter complex formation (McCoy et 
al.,2008, Ogawa et al.,2005). ANXA1 can constitutively activate NF-κB in 
breast cancer cells through the interaction with the IKK complex (Bist et al., 
2011) and ANXA1 deficient macrophages exhibit an aberrant expression of 
TLR4 (Damazo et al., 2005). All the studies above indicate that ANXA1 plays 
a role in TLR signaling. To understand the mechanism better our lab studied 
ANXA1 in context of TLR 3 and 4 and found that ANXA1 C terminus of 
ANXA1 directly associates with TANK-binding kinase 1 to regulate IRF3 
translocation and phosphorylation (Bist et al., 2013).  Influenza virus, being a 
ssRNA virus is a natural ligand for TLR7 and hence it will be interesting to 
study role of ANXA1 in context of Influenza virus. 
 
1.3. Influenza Virus 
 
Influenza virus is a single stranded RNA virus and belongs to the 
orthomyxoviridae family. These are enveloped viruses usually spherical in 
shape measuring around 80-120 nm in diameter. Influenza viruses can be 
divided into three subtypes A, B and C based on the antigenic differences 
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between the matrix and nucleoproteins (M and NP) that exist in these viruses. 
They also differ in morphology, host range surface glycoproteins and genome 
organization. The subtype A is the most virulent type and is responsible for all 
the pandemics of influenza in the past. It can be further divided based on the 
surface glycoproteins haemagglutinin (HA) and neuraminidase (NA). There are 
16 HAs and 9 NAs known so far which combine to form distinct serotypes i.e 
antibodies to one serotype do not cross-react with others (Lamb and Krug, 
2001). 
 
1.3.1. Health threat and Global Impact of Influenza Viruses 
 
The 20th century has seen three influenza pandemics. A pandemic is an 
epidemic that spreads on a worldwide scale and infects a large part of human 
population. The “H1N1 Spanish flu” in 1918 after the First World War took 
approximately 50 million lives, more than the deaths in the war. The following 
two pandemics the “H2N2 Asian flu” in 1957 and “H3N2 Hong Kong flu” in 
1968 resulted in about two million deaths (Johnson & Mueller, 2002; 
Kilbourne, 2006). The current information supports that wildbirds are the 
reservoirs for the new evolving strains since they are the natural hosts and 
contain all subtypes of HA and NA glycoproteins (Webster, 1997; Zambon, 
2001). The first case of direct transmission from birds to human was observed 
in 1997 during the avian influenza H5N1 outbreak (Subbarao et al., 1998). 
Until 2009 few outbreaks of avian influenza were observed throughout the 
world. Since this strain was highly pathogenic, had high mortality rate (Komar 
& Olsen, 2008) it was suspected to cause another pandemic and had the 
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potential to kill around 5-150 million people. Following this was the 2009 
H1N1 pandemic which spread rapidly around the globe. From the 
announcement of its first case, it spread to 43 countries within a span of one 
month. The most recent are the H7N9 outbreaks in China in April, 2013. The 
cases have drastically reduced within a month due to the containment measures 
but it is suspected to re-emerge as the weather becomes cooler and has a high 
pandemic potential (CDC report, 2013).  
Influenza pandemics are the result of antigenic shift or the reassortment of the 
genome of influenza virus. Since the vRNA is segmented and present on 8 
different segements it allows mixing of RNA if more than one virus particle 
infects a cell. It can also take place in wild fowls where all 16 types of HAs and 
9 NAs are present. This reassortment allows exchange of large proportions of 
the virus genome creating a novel progeny virus that leads to the change of the 
host it can infect. Due to changes in the HA and NA the virus overcomes host 
immunity and spreads uncontrollably leading to pandemics (Parrish & 
Kawaoka, 2005). Influenza A viruses also mutate due to antigenic drift. 
Because of the absence of RNA proofreading enzymes, RNA dependant RNA 
polymerase makes errors which leads to minor changes in the antigens. This 
may lead to epidemics and therefore it necessitates the update of influenza 
vaccines annually. Influenza B and C undergo antigenic shifts only compared 






1.3.2. Signs and Symptoms 
 
Symptoms of influenza include fever and chills, nasal congestion, cough, 
running nose, body aches, fatigue, headache and watering eyes under non-
pandemic conditions. Approximately 33% of the people infected with influenza 
virus are asymptomatic (Carrat et al., 2008). The incubation period of the virus 
is about 2 days after which the symptoms appear. The infection is usually  
cleared by the host immune system unless it develops complications which are 
generally observed in either very young (less than 5 years) or old people (more 
than 65  years) due to weakened immune system. It is difficult to diagnose 
influenza only on the basis of its symptoms as these are similar to the 
symptoms caused other respiratory viruses like rhinovirus or parainfluenza 
virus but sudden high fever and extreme fatigue indicate a flu infection (Eccles, 
2005). Influenza infection can induce hemorrhagic-bronchitis and pneumonia 
the above mentioned risk groups (Taubenberger & Morens, 2008) .Secondary 
bacterial infections adds to the risk and lead to more pulmonary complications. 
It is therefore advisable to treat patients with antibiotics along with antivirals in 
case of severe infections (Morens, Taubenberger, & Fauci, 2008).   
 
1.3.3. Structure of Influenza virus 
 
Influenza viruses are usually spherical 80-100nm in size (Horne, Waterson, 
Wildy, & Farnham, 1960). It consists of a segmented genome encapsulated by 
the envelope. The surface glycoproteins hemagglutinin (HA) and 
neuraminidase (NA) spike out from the envelope and the ribonucleoprotein 
consisting of the viral polymerase and non-structural proteins reside within the 
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core (Laver & Valentine, 1969). The virus obtains its lipid bilayer from the 
plasma membrane during budding (Klenk & Choppin, 1970). Below the lipid 
bilayer is another layer of viral membrane Matrix protein (M1). The core 
containing the ribonucleoprotein (RNP) is divided into eight segments. Each 
RNP contains four proteins namely the nucleoprotein (NP), polymerase basic 1 
(PB1), polymerase basic (PB2), polymerase acid (PA) and a segment of RNA. 
The RNP complex has RNA-dependant RNA polymerase activity (Chow & 
Simpson, 1971; Inglis, Carroll, Lamb, & Mahy, 1976).  The eight segments 
therefore encode seven structural (PB1, PB2, PA, HA, NA, NP and M1) and 
three non-structural (NS1, NS2 and M2) proteins. NS2 and M2 are splice 
variations of NS1 and M1 and a recently discovered protein PB1-F2 is the 
result of an alternate open reading frame of PB1 (W. Chen et al., 2001; Lamb 
& Choppin, 1979). 
 
1.3.3.1. RNA segments 1, 2 and 3: PB1, PB2 and PA  
These three proteins are the transcriptase associated proteins. They derive their 
nomenclature from isoelectric focussing and polyacrylamide electrophoresis. 
The faster migrating basic protein coded by segment 1 is PB2, the slower 
migrating protein in segment 2 is PB1 and acidic protein in segment 3 is the 
PA (Horisberger, 1980). PB1 is responsible for the addition of nucleotides 
during RNA chain elongation. It also possesses the endonuclease activity for 
snatching the 5’ cap from host mRNA to provide primer for mRNA synthesis 
(Braam, Ulmanen, & Krug, 1983) (M. L. Li, Rao, & Krug, 2001). PB2 plays a 
role in replication and transcription initiation by binding to the host cap 
structure (Blaas, Patzelt, & Kuechler, 1982) while PA plays a role in vRNA 
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synthesis (Palese, Ritchey, & Schulman, 1977). A few known inhibitors of the 
polymerse are 2,4-dioxobutanoic acid and 2,6-diketopiperazine derivatives, 
that inhibit the endonuclease activity (PB1) of the influenza virus polymerase. 
Ribavirin, another antiviral, and several other nucleotide analogs inhibit viral 
polymerase complex, but toxicity remains a problem  (Tomassini et al., 1994). 
 
   
Figure 1.4 Structure and genome organization of influenza virus 
 (A) HA NA and M2 are the three proteins embedded in host derived plasma 
membrane. Beneath the lipid bilayer is a layer of M1 which is associated with 
both RNP and envelope. The core consists of 8 segments or RNA with RNP 
proteins PB1, PB2 and PA. (B) The figure shows the 8 RNA segments and 
their splice variants in order of their length. (A) (Horimoto & Kawaoka, 2005) 
(B)Martinez-Sobrido Laboratory Resources. 
 
1.3.3.2. RNA segment 4: Hemaglutinnin 
HA is a glycoprotein responsible for viral adsorption. It is so named because of 
its ability to agglutinate red blood cells (RBCs). It is the most important viral 




major cause of influenza epidemics and pandemics. One of the functions of HA 
include viral attachment to the host cell (Lazarowitz & Choppin, 1975). The 
viral pathogenicity depends on the proteolytic cleavage of HA0 to HA1 and 
HA2. Due to this cleavage the hydrophobic region of HA2 containing a fusion 
peptide is exposed. Low pH drastically changes the structure of HA and the 
fusion peptide inserts itself into endosomal membrane to bring it closer to viral 
membrane and hence cause fusion. Presence of more than one HA forms a pore 
through which the RNPs can enter the cytoplasm (Skehel et al., 1982). Quinone 
derivatives inhibit the conformational changes in HA and thus prevent 
infection (Bodian et al., 1993). 
 
1.3.3.3. RNA segment 5: The Nucleocapsid protein 
The NP protein is an important constituent of the RNP complex that coats the 
RNA. It also interacts with the Polymerase complex comprising of PB1, PB2 
and PA. It aids in the process of nuclear import of the vRNA (Cros, Garcia-
Sastre, & Palese, 2005) 
1.3.3.4. RNA segment 6: The Neuraminidase  
NA is a surface glycoprotein which is mushroom shaped with a stalk and a 
head (Wrigley, Skehel, Charlwood, & Brand, 1973). It has a role to play in the 
budding of the virus from host membrane as it hydrolytically cleaves 
glycosidic bonds of the neuraminic acid (sialic acid) and frees the virus from 
any sialic acid containing structures (Palese & Schulman, 1974). It is also 
believed to play a role early in infection facilitating the entry of virus (M. N. 
Matrosovich, Matrosovich, Gray, Roberts, & Klenk, 2004) or late 
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endosomal/lysosomal trafficking (Suzuki et al., 2005). NA inhibitors are potent 
antivirals. Zanamivir  (von  Itzstein  et  al.,  1993)    and oseltamivir (W. Li et al., 
1998) are the two more successful ones. 
1.3.3.5. RNA segment 7: The Matrix (M1) and Ion channel (M2) proteins 
Segment 7 produces two viral proteins M1 and M2 due to alternative splicing 
of the mRNA. The M1 is the most abundant protein of the virus. It forms a 
shell beneath the lipid bilayer (Schulze, 1972). It interacts with both the surface 
glycoproteins and the RNPs and form a kind of bridge between the two 
(Nayak, Hui, & Barman, 2004). It is known to play an important role in virus 
assembly by bringing all the viral components to the assembly site and is 
indispensable for the formation of viral particles (Gomez-Puertas, Albo, Perez-
Pastrana, Vivo, & Portela, 2000). The M1 protein is synthesized on free 
ribosomes and it lacks a signal peptide making its route to the plasma 
membrane different from HA and NA. 
M2 protein is an ion channel protein that is acid gated and is selective for H+ 
ions (Mould et al., 2000). It plays a role in the uncoating and release of RNP 
into the cytoplasm. When the HA mediated fusion occurs between the viral and 
the endosomal membrane it allows the influx of H+ into the virus particle to 
cause acidification of the viral core that breaks the protein-protein interactions 
to free the RNP from the M1 protein into the cytoplasm (Matlin, Reggio, 
Helenius, & Simons, 1981). Amantadine and rimantadine are the antivirals and 
inhibits the activity of M2 protein thus affecting the uncoating process (Sugrue 




1.3.3.6. RNA segment 8: NS1 and NS2  
Segment 8 is the smallest of the 8 segments and codes for two proteins that are 
found only in infected cells, the non-structural proteins 1 and 2. The NS2 
mRNA is translated in +1 reading frame both splice variants overlap by 70 
amino acids (Inglis & Brown, 1981).  NS1 inhibits interferon synthesis by 
binding to the intracellular dsRNA. Production of IFN-β depends upon the 
transcription of NF-κB, AP-1 and IRF-3. All these transcription factors are 
reported to be strongly activated in NS1 mutants (Ludwig et al., 2002; Talon et 
al., 2000; X. Wang et al., 2000). It is also involved in the inhibition of PKR, a 
host protein that phosphorylates elF2α and ceases protein synthesis thus 
preventing viral replication. This function of NS1 is also due to its dsRNA 
binding ability. It sequesters the dsRNA which is required for the activation of 
PKR (Hatada, Saito, & Fukuda, 1999).  NS1 interacts with cleavage and 
polyadenylation specificity factor (CPSF) and poly (A)-binding protein II. This 
interaction inhibits the processing of pre-mRNAs and thus they are retained in 
the nucleus. Since the host antiviral response depends a lot on transcriptional 
activation of gene this inhibition delays or in some cases aborts the immune 
response (Noah, Twu, & Krug, 2003) 
NS2 is found to interact with the nuclear export protein crm1 and also with 
M1. The RNP-M1-NS2 complex is formed in the nucleus and is responsible for 
the export of RNP from nucleus via interaction with the host cellular export 





1.3.4. Viral Life Cycle 
 
The virus life cycle begins with the entry of virus into the host cell. The HA 
protein present on the surface of virus form spikes and attaches to the sialic 
acid residues on the surface of cells (Skehel & Wiley, 2000). HA is composed 
of HA1, the receptor domain and HA2, the fusion peptide linked by disulphide 
bonds (Q. Huang et al., 2003). Upon binding, the virus enters the cell by 
receptor mediated endocytosis in an endosome (Skehel & Wiley, 2000). The 
low pH in endosomes brings conformational changes in HA and exposes the 
HA2 subunit which inserts itself into the endosomal membrane bringing about 
fusion of viral and endosomal membranes. The acidic environment also opens 
the M2 channel and acidifies the core resulting in the release of vRNP in the 
cell cytoplasm (Pinto & Lamb, 2006a, 2006b). 
The viral transcription and replication happens in the nucleus therefore vRNP 
have to be imported into the nucleus. This is done with the nuclear localization 
signals present on all the proteins that constitute the vRNP (Boulo, Akarsu, 
Ruigrok, & Baudin, 2007). The import takes place with the help of cell’s active 
import machinery involving the Crm1 dependent pathway.  
Once inside the nucleus the negative strand is transcribed to positive sense to 
serve as the template for the production of vRNA. Viral RNA dependant RNA 
(RdRp) polymerase replicates the genome. No primer is required for this 
process because of the sequence complementarity between the extreme 5’ and 
3’ ends which results in base-pairing between the ends and formation of 
various cork screw configurations (Crow, Deng, Addley, & Brownlee, 2004).  
The mature mRNA contains a 5’ cap and poly (A) tail.  During transcription 
the RdRp snatches the cap with 10-15 extra nucleotides from the host RNA and 
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uses it to prime the viral transcription (Plotch, Bouloy, & Krug, 1979). Each 
viral segment contains five to seven U residues about 17 nucleotides before the 
5’ end. The RdRp stutters onto this sequence due to steric hindrance as it nears 
the end   and moves back and forth over this stretch forming the poly(A) tail 
(Poon, Pritlove, Fodor, & Brownlee, 1999). 
The negative sense vRNPs are exported out of the nucleus (Shapiro, Gurney, & 
Krug, 1987). M1 binds to both vRNPs and NS2. NS2 can then export the 
complex out of the nucleus by binding to Crm1 and causing GTP hydrolysis 
that occurs normally in Crm1 dependant export pathway (Boulo, et al., 
2007).The exit of vRNPs from the nucleus is from the apical side of the 
infected nuclei (Elton, Amorim, Medcalf, & Digard, 2005). 
After vRNPs are exported out of the nucleus they are packaged into the viral 
envelope and the newly formed virions bud out from the apical side of the 
membrane. The virus uses host cell’s plasma membrane to form the lipid 
bilayer of the envelope and HA, NA and M2 must be present for the formation 
of the virions (Nayak, et al., 2004). Packaging sequences are present in the 
coding and non-coding regions of viral segments (Liang, Hong, & Parslow, 
2005). The last step before the virus exits the cell is the cleavage of sialic acid 
residues from glycoproteins by the NA protein so that the virus can be released 





Figure 1.5 Replication and transcription of Influenza virus. 
The virus is adsorbed into the cell via receptor mediated endocytosis and fuses 
with the endosomes. The low pH in the endosome results in the release of 
RNPs into the cytoplasm. The RNP then moves into the nucleus and serves as 
the template for transcription. The viral proteins are synthesized from mRNA. 
The replication of the vRNA is through a positive sense intermediate cRNA. 
The viral proteins then move to the apical plasma membrane where they are 




1.3.5. Influenza Tropism  
 
Most influenza virus strains have restricted tissue tropism but certain strains 
can circulate in more than one species. Though the host factors restrict virus 
infection in a new species the previous pandemics reiterate the fact that due to 
gene assortment the virus is able to overcome these host barriers (Medina & 
Garcia-Sastre, 2011). In general the specificity and affinity of HA is one of the 
determining steps in host tropism and transmission. The virus infects the cell 
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by binding to the cell surface glycoproteins through HA. The tropism of 
influenza virus is based on the differences in sialic acid glycosylation. The 
human viruses (containing H1-H3) recognize receptors with terminal α-2,6-
Silaic acid moieties which are usually present on the bronchial epithelial cells 
of the human upper respiratory tract (URT) (Stevens et al., 2006). In contrast to 
this the avian influenza viruses bind to a slightly different moiety i.e galactose 
linked α-2,3-Sialic acid which is abundant on the epithelial cells present in the 
intestine of the birds and lower respiratory tract (LRT) of the humans (M. 
Matrosovich, Zhou, Kawaoka, & Webster, 1999). Though α-2,3-SA is also 
present in non-ciliated cells  of the lower tracheal epithelium these cells are in 
minority and the density of receptors on these cells is very low , which explains 
the low transmissibility of avian viruses in humans (Maines et al., 2006). 
However, pigs contain both α-2,6-SA and α-2,3-SA in their trachea and hence 
they acts as “mixing vessels” for the reassortment of human and avian strains 
resulting in the production of a new pandemic potent strain (Ito et al., 1998). 
Turkeys, pheasants, quail and guinea fowl also contain both receptor types in 
their intestines and respiratory tract and can thus act as “mixing vessels”.  
1.3.6. Immune responses against Influenza virus 
 
The first line of defence against the influenza virus is innate immune system. 
Viral nucleic acids act as pathogen associated molecular patterns (PAMPS) and 
are recognized by pathogen recognition receptors (PRRs) to activate the 
downstream signalling pathways for the antiviral response. There are three 
classes of viral nucleic acids namely ssRNA, dsRNA and DNA that can elicit 
an immune response. These nucleic acids in the cytoplasm of infected cells can 
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be sensed by ubiquitously expressed dsRNA-dependent protein kinase R 
(PKR) , retinoic acid inducible gene I (RIG-I), melanoma differentiation-
associated gene 5 (MDA-5) or cell specific TLRs (described earlier). Each of 
them will be discussed in detail in the following sections. 
1.3.6.1. PKR 
PKR is serine/threonine kinase that recognizes dsRNA. It is an IFN inducible 
gene. Upon RNA binding the two RNA binding domains dimerize and causes 
autophosphorylation and thus activation of its enzymatic activity (Garcia-
Sastre & Biron, 2006). PKR inhibits cellular and viral protein translation by 
phosphorylating eukaryotic initiation factor 2α (eIF2α). This impairs the 
GDP/GTP exchange leading to reduced production of GTP-eIF2α which is 
essential for translation (Samuel, 2001). PKR can regulate NF-κB and IFN-
stimulated genes to amplify the IFN response. 
1.3.6.2. RIG-I and MDA-5 
RIG-I and MDA-5 are RNA helicases that recognize the viral RNA in the 
cytoplasm. Both helicases belong to the DExD/H box-containing RNA helicase 
family with a conserved domain structure. They contain two N-terminal 
caspase recruitment domains (CARD) and one C-terminal DExD/H box 
helicase domain (Unterholzner & Bowie, 2008). The IFN-β promoter 
stimulator-1 (IPS-1) also called mitochondrial anti-viral signalling (MAVS) or 
virus induced signalling adapter (VISA), is the adapter molecule that also 
contains a CARD domain homologous to that of RIG-I and MDA-5. The 
CARD-CARD interaction between these helicases and their adapter leads to 
the activation of NF-κB, IRF3 and IRF7 (Kawai et al., 2005; Seth, Sun, Ea, & 
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Chen, 2005; Sun et al., 2006; Xu et al., 2005). IPS-1 is located in the outer 
mitochondrial membrane by a transmembrane domain which is essential for 
activation of downstream pathways. 
IPS-1 makes use of IκB Kinase α (IKKα) , IKKβ , IKKε and Tank binding 
kinase (TBK-1) to activate the downstream signalling pathways.  IKKγ 
facilitates the recruitment of TBK-1 and IKKε to IPS-1-TRAF3 complex. 
TRAF3 serves as a bridge for the interaction of these kinases with IPS-1 (Saha 
et al., 2006). IPS-1 also interacts with TRAF2, TRAF6, FADD and RIP1 which 
are involved in NF-κB activation (Xu, et al., 2005). 
Originally, both RIG-I and MDA-5 were thought to be the sensors for dsRNA 
but generation of RIG-I and MDA-5 Knockout mice revealed that the function 
of the two helicases is not redundant. MDA5 recognizes picornaviruses while 
RIG-I recongnizes viruses like Sendai virus, Influenza virus etc. (Kato et al., 
2006). It was observed that viruses that produce large amounts of dsRNA 
during replication were detected by MDA-5 while those producing small 
amounts of dsRNA only as an intermediate were detected by RIG-I. More 
experiments lead to the understanding that MDA-5 recognizes a dsRNA 
structure while RIG-I recognizes ss or ds RNAs with a triphosphate at the 5’ 
end (Pichlmair et al., 2006). 
Another intriguing topic that is studied in detail is how self RNA molecules are 
distinguished from viruses RNAs. Ribosomal RNA, transfer RNA and pre-
micro RNAs possess a 5’ monophosphate, the mRNAs and small nuclear 
RNAs possess methylguanosine cap and some other RNAs possess 
pseudouridine or 2’-O-methylation that keep them from detection by RIG-I 





Figure 1.6 RIG-I and MDA-5 Signalling 
RIG-I and MDA-5 are cytoplasmic sensors that recognize 5’ tri-phosphate 
RNA or dsRNA respectively. Both these sensors and their Adaptor protein 
MAVS contain CARD domains. Due to CARD-CARD interaction between 
these helicases and their adapter leads to the activation of NF-κB, IRF3 and 
IRF7 (http://en.wikipedia.org/wiki/File:Simon_%28RIG-I_and_Mda5%29.jpg). 
     
1.3.6.3       Influenza virus Induced signalling cascades 
Influenza infection triggers various signalling pathways and activates several 
transcription factors like NF-κB, AP-1, IRFs, signal transducers and activators 
of transcription (STATs) and nuclear factor IL-6 (NF-IL-6) (Julkunen et al., 
2001). Several cytokines possess NF-κB binding sites in their promoters; 
therefore for the production of cytokines, activation of NF-κB is important. It 
has also been shown that NF-κB signalling is important for efficient virus 
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propagation (Nimmerjahn et al., 2004). Upon infection, NF-κB is activated in a 
biphasic manner. It is first detectable 1hr post infection and the later activation 
depends on viral replication and protein synthesis (Ronni et al., 1997). Its 
activation is dependent upon activation of IKK in response to viruses.  
Another important pathway that is activated is the MAPK pathway. Influenza 
activates several members of the MAPK family such as ERK1/2, p38 and JNK 
(Kujime, Hashimoto, Gon, Shimizu, & Horie, 2000) resulting in the activation 
of AP-1. Unlike NF- κB, AP-1 requires viral replication for activation and is 
not affected by over expression of viral proteins (Flory et al., 2000).  
TLRs 3, 7 and 9 signalling lead to the activation of IRFs 1, 3, 5 and 7, IRFs 3 
and 7 being the most critical. IRF3 and IRF 7 are present in the cytoplasm and 
translocate to the nucleus upon phosphorylation of the C-terminus serine 
residues (Marie, Durbin, & Levy, 1998). Both these transcription factors 
undergo dimerization to activate their targets. The activation of IRF7 depends 
on the STAT1-STAT2-IRF9 complex called the Interferon stimulated gene 
factor 3 (ISGF3). IRF3 mainly leads to the production of IFN β (and IFN α4) 
whereas IRF7 can lead to the production of both IFN β and all forms of IFN α. 
IRF3 homodimer or IRF3/IRF7 heterodimer can produce small amount of 
interferons which bind to its receptor IFNAR resulting in robust production of 






1.3.7. Humoral Response 
 
Humoral immunity provides long term protective effects through neutralizing 
antibodies against HA and NA proteins of the virus. They prevent reinfection 
by an antigenically similar or identical strain. Neutralizing antibodies are the 
basis of seasonal vaccinations and have to be periodically updated due to rapid 
mutations in the viral coat. They also play a role in viral clearance during the 
primary challenge since mice deficient in B cells have compromised clearance 
of virus from the respiratory tract (Kris, Asofsky, Evans, & Small, 1985). The 
main influenza-specific antibody isotypes are IgA, IgG and IgM. Mucosal or 
secretory IgA antibodies are produced locally in the infection site and 
transported along the mucus of the respiratory tract thus, conferring local 
protection from infection of airway epithelial cells. These antibodies are also 
able to neutralize influenza virus intracellularly (Mazanec, Coudret, & 
Fletcher, 1995). IgAs are produced rapidly after influenza virus infection and 
the presence of these antibodies indicates a recent infection (Rothbarth, Groen, 
Bohnen, de Groot, & Osterhaus, 1999). IgG antibodies predominantly 
transudate into the respiratory tract and provide long-lived protection (Murphy 
et al., 1982). IgM antibodies initiate complement mediated neutralization of 
influenza virus and are a hallmark of primary infection  (Fernandez Gonzalez, 
Jayasekera, & Carroll, 2008). 
 
1.3.8. T cell Response 
 
Influenza infection leads to the proliferation of both CD4+ and CD8+ T cells. 
CD4+ T cells mainly secrete cytokines like IL-4 and IL-13 to promote B cell 
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responses and IFN-γ and IL-2 to aid cellular responses. CD8+ T cells are 
responsible for the lysis of the infected cells and thus prevent the production of 
progeny virus. Upon infection these cells are activated in the lymphoid tissues 
and recruited to the site of infection. CD8 T-cells recognise infected cells by 
interaction of the T cell receptor (TCR) with viral antigens loaded onto major 
histocompatibility complex I (MHC I) on the cell surface. The cytolytic 
activity is due to the perforins and granzymes. Perforins permeabilize the 
membrane of the infected cells and granzymes enter these to induce apoptosis. 
They can also induce apoptosis through Fas and TRAIL interactions (Brincks, 
Katewa, Kucaba, Griffith, & Legge, 2008; Topham, Tripp, & Doherty, 1997). 
Effector CD8 T cells can secrete large amounts of cytokines like IFN-γ, TNF-α 
and GM-CSF. Human CTL induced by influenza virus infection are mainly 
directed against NP, M1 and PA proteins (Gotch, McMichael, Smith, & Moss, 
1987). These proteins are highly conserved and therefore CTL responses 
display a high degree of cross-reactivity unlike humoral immunity, even 
between different subtypes of influenza A virus 
 
1.3.9.  Annexins and viruses 
 
As discussed above the one of the important host defence mechanism against 
Influenza is triggering the signalling through TLR pathway and a novel player 
in this pathway is ANXA1. Whether and how ANXA1 is involved in 
virus‐triggered signalling is unknown. Mass spectrometry data obtained by our 
lab shows that ANXA1 might be involved in anti‐viral immunity. Annexins 
have been known to be involved in infectious diseases such as Tuberculosis 
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(Gan et al., 2008), HIV (Ryzhova et al., 2006) and Hepatitis C (Backes et al., 
2010). Importantly, Annexin V was identified as a protein binding to the 
proteins of Influenza virus (Otto, Gunther, Fan, Rick, & Huang, 1994). 
Annexin V helps the entry of influenza virus into the cell. In addition, it has 
also been proposed that annexins might be serving as the receptor for the 
viruses (R. T. Huang, Lichtenberg, & Rick, 1996). Annexin II has been shown 
to support viral replication when incorporated in Influenza virus by converting 
plasminogen into plasmin (LeBouder et al., 2008). Annexin 1 were also found 
to inhibit Cytomagalovirus infection (Derry, Sutherland, Restall, Waisman, & 
Pryzdial, 2007). Furthermore it was reported that ANXA1 levels were 
upregulated in porcine monocytes infected with swine flu virus (Katoh, 2000). 
Another report shows human Annexin 6 binds to cytoplasmic tail of the ion 
channel protein (M2) of the Influenza virus and negatively modulates infection 
(Ma et al., 2012). Recently published data from lab shows the ANXA1 
regulates TLR-mediated production of IFN-β by interacting with (TBK-1) in 
macrophages upon activation with LPS or Poly(I:C) (Bist, et al., 2013). This 
led us to postulate that ANXA1 could be involved in anti‐viral immunity. It is 
known that Influenza virus induces apoptosis and ANXA1 also plays a role in 
apoptosis however it is not known if ANXA1 plays a role in influenza induced 
apoptosis. Apoptosis is discussed in detail in the next section.  
1.4. Apoptosis 
 
The term Apoptosis is was coined by John Kerr in 1972 referring to the 
formation of small apoptotic bodies formed during the disintegration of the cell 
(Kerr, Wyllie, & Currie, 1972). It also also known as Programmed cell death 
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and is important for the development, tissue homeostasis and effective immune 
sytem. Due to its importance any disturbance in its regulation brings out 
numerous pathological conditions like autoimmune disorders and cancers 
(Cory & Adams, 2002). Once the apoptotic switch is triggered it results in the 
activation of a family of cysteine proteases known as caspases. This switch 
however can be activated either by transmembrane receptor-mediated 
interactions, also known as extrinsic pathway (Strasser, O'Connor, & Dixit, 
2000) or by intracellular damage, known as the Intrinsic pathway (Gross, 
McDonnell, & Korsmeyer, 1999). 
 
1.4.1. The Receptor mediated/ Extrinsic Pathway 
 
The receptor mediated pathway involves death receptors that are members of 
TNF receptor gene family like Fas (CD95) and TNF-R1 (Locksley, Killeen, & 
Lenardo, 2001). These receptors contain a cysteine-rich extracellular domain 
and a cytoplasmic death-domain of about 80 amino acids (Ashkenazi & Dixit, 
1998) . This pathway activates caspas-8 and caspase 10 in humans (initiator 
caspases) via Fas-associated death domain (FADD). FADD associates with 
pro-caspase 8 due to dimerization of homologous death effector domains 
(DEDs) which leads to the formation of Death inducing signalling complex 
(DISC). DISC brings zymogens in close proximity resulting in auto-catalytic 
activation of pro-caspase 8 (Kischkel et al., 1995). After the activation of 
caspase-8 the execution pathway if triggered which involve the downstream 
caspases. The extrinsic pathway can be inhibited by a protein called c-FLIP, a 
dominant negative caspase-8 which binds to FADD and pro-caspase 8 leading 
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to the formation of an inactive DISC (Kataoka et al., 1998; Scaffidi, Schmitz, 
Krammer, & Peter, 1999). Apart from Fas there are other death receptors as 
well like DR4, DR5, CAR1, TNF-R1 and p75 which are activated by TNF-
related apoptosis inducing ligand (TRAIL). These receptors are present on 
most cell types and recruit FADD and induce DISC in a similar fashion as Fas 
(Lawen, 2003). TRAIL also plays a role in the apoptosis of autoreactive T cells 
(Lamhamedi-Cherradi, Zheng, Maguschak, Peschon, & Chen, 2003). TNF-R1 
unlike Fas can also signal for proliferation depending upon the downstream 
molecules recruited to DISC. TNF-R associated death domain protein is the 
one that signals either via FADD to induce apoptosis or RIP1 and TRAF to 
promote survival (MacEwan, 2002). 
 
1.4.2. The Intrinsic pathway 
 
The intrinsic pathway leads to the initiation of apoptosis due to the intracellular 
stimuli which directly acts on mitochondria. This leads to the release of 
mitochondrial proteins into cytoplasm due to opening of the mitochondria 
permeability transition (MPT) pore and loss of mitochondria transmembrane 
potential, a process known as mitochondria outer membrane permeabilisation 
(MOMP) (Ekert & Vaux, 2005). The released proteins can be divided into 2 
main groups. The first one consists of cytochrome c, Smac/DIABLO and the 
serine protease HtrA2/Omi (Du, Fang, Li, Li, & Wang, 2000; Elmore, 2007; 
Garrido et al., 2006). Cytochrome c induces a conformational change in 
Apoptotic protease activating factor (Apaf-1) which allows it to recruit 
procaspase-9 into the resulting giant complex known as “apoptosome” (Hill, 
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Adrain, Duriez, Creagh, & Martin, 2004). Mature caspase-9 is formed from its 
precursor zymogen due to allosteric interactions and dimerization rather than 
cleavage (Rodriguez & Lazebnik, 1999). Smac/DIABLO and HtrA2/Omi 
promote apoptosis by inhibiting the inhibitors of apoptosis proteins (IAPs). The 
second group of mitochondrial proteins consists of caspase dependent 
Apoptosis inducing factor (AIF) or independent Caspase activated DNase 
(CAD) endonucleases which translocates to the nucleus and leads to DNA 
fragmentation (Susin et al., 2000). 
 
The release of cytochrome c is a crucial event in apoptosis and hence must be 
tightly regulated. This task is carried out by Bcl-2 family of proteins. This 
family is divided into 3 subgroups depending on the structural and functional 
characteristics. The Bcl-2 like proteins Bcl-2, Bcl-XL,  Bcl-w, Mcl-1 and A1 are 
inhibitors of apoptosis, while Bax, Bak and BH3-only proteins are pro-
apoptotic. BH3 only proteins trigger the cytochrome release by activating Bax 





Figure 1.7 Structure of Bcl-2 family proteins 
The proteins are divided based on the Bcl-2 homology (BH) domains. Most 
Bcl-2 like proteins have all 4 BH domains, the “multidomain” proteins share 3 
(BH1, BH2 and BH3) and the BH3-only proteins just have 1 BH domain (G. 
Hacker & Weber, 2007).  
 
 
Localization of Bcl-2 family members is important for their function. Bcl-2 is a 
membrane protein even in healthy cells, Mcl-1 is cytosolic and the others Bcl-
w and Bcl-XL bind to membranes only upon the apoptotic stimuli. (Hsu, 
Wolter, & Youle, 1997). Bax is a cytosolic protein while Bak is bound to the 
membrane in healthy cells (Griffiths et al., 1999; Mikhailov et al., 2001). Upon 
stimulation Bax migrates to the mitochondrial membrane and undergoes 
conformational changes. Bak also undergoes conformational change and forms 
oligomers. Bax or Bak oligomers coalesce to from larger complexes 
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(Mikhailov et al., 2003) that can form pores in the mitochondria leading to 
cytochrome c release (Antonsson, Montessuit, Lauper, Eskes, & Martinou, 
2000). 
A few mechanisms have been proposed for the exact apoptotic pathway but 
none has been proven fully. An example of a cross-talk between extrinsic and 
intrinsic pathway is mitochondrial damage by Fas pathway and caspase-8 
cleavage of Bid (Igney & Krammer, 2002). Bad is regulated by serine 
phosphorylation and once phosphorylated it is trapped by 14-3-3 (phophoserine 
binding molecules). Upon unphosphorylation it moves to mitochondria and 
releases cytochrome c (Zha, Harada, Yang, Jockel, & Korsmeyer, 1996). Bad 
can also associate with Bcl-2 and Bcl-XL neutralizing their anti-apoptotic 
effects (E. Yang et al., 1995). Bcl-2 and Bcl-XL when free inhibit the release of 
cytochrome c and control the activation of caspases (Newmeyer et al., 2000). A 
few other members of bcl-2 family like Puma and Noxa induce apoptosis in p-
53 dependant manner. Puma can activate Bax and lead to lowering to 
mitochondrial potential resulting in cytochrome c release (Liu, Newland, & Jia, 
2003). Noxa on the other hand migrates to the mitochondria and sequesters 
anti-apoptotic proteins resulting in caspase 9 activation (Oda et al., 2000). 
Mechanism for activation of Bax and Bak is still unclear, however it is 
believed that BH3-only protein Bid plays an important role in their activation 
(Desagher et al., 1999). Three models have been proposed for the interplay 
between the Bcl-2 family members. (A) Bcl-2 proteins inhibit the activation of 
Bax/Bid by controlling direct interactions of BH3-only proteins with Bax/bak. 
(B) BH3-only proteins indirectly activate Bax/BAk by inhibiting Bcl-2 protein 
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activities. (C) A few BH3-only proteins activate Bax/Bak while others inhibit 
Bcl-2 proteins (Adams, 2003).  
 
Figure 1.8 The two main pathways of apoptosis 
The receptor mediated pathway (on the left) is triggered by Fas/Cd95 binding 
to its receptor and acativating caspase-8 via the adapter molecule FADD. The 
intrinsic pathway is activated by the intracellular insults like DNA damage in 
this case and leads to the release of cytochrome c, AIF and Smac/DIABLO due 
to the interplay between Bcl-2 family members. The released cytochrome c 
aids the formation of apoptosome comprising of itself, procaspase-9 and Apaf-
1. Both receptor mediated and intrinsic pathways culminates at the point of 
activation of executioner caspases like caspase 3, 6 or 7 resulting in the 










1.4.3. The Execution Pathway 
 
Both extrinsic and intrinsic pathways culminate in the execution phase, which 
is considered as the final step of apoptosis. Activation of the caspases bring 
about the initiation of this step. There are 14 capases known so far and they can 
be divided into three classes (1) the initiator caspases that are described earlier 
in the extrinsic and intrinsic pathway, characterised by long prodomains 
containing either DED domains (eg. Caspase 8 or 10) or a caspase recruitment 
domain (CARD) (eg. Caspase 2 and 9). (2) The executioner caspases 
containing short prodomains (caspase 3, 6 and 7) and (3) Caspases playing a 
role in cytokine production rather than apoptosis (Grutter, 2000) . Initiator 
caspases cleave executioner caspases and activate them. Execution caspases 
then activate endonucleases and proteases that degrade nuclear material and 
cytoplasmic and nuclear proteins. The executioner caspases have various 
substrates like Poly (ADP-ribose) polymerase (PARP), cytoskeletal protein α-
fodrin, NuMA etc. which bring about the morphological and biochemical 
changes in the dyeing cells (Slee, Adrain, & Martin, 2001). 
Caspase-3 is considered as the most important execution caspase. It realeases 
the endonuclease CAD from its inhibitor ICAD and brings about the degration 
of the chromosomal DNA (Sakahira, Enari, & Nagata, 1998). It also cleaves 
Gelsolin, an actin binding protein resulting in the disruption of cytoskeleton, 
cell division and signal transduction (Kothakota et al., 1997). Apoptosis ends 
with the phagocytocis of apoptotic cells due to the “eat me” signals like 
flipping of the PS molecule towards the outer leaflet of the cell, relayed from 




1.4.4. Influenza and Apoptosis  
 
Apoptosis is a powerful strategy used by the host to inhibit viral propagation 
but over time many viruses have evolved to control the apoptotic response in 
the host (Galluzzi, Brenner, Morselli, Touat, & Kroemer, 2008). Three out of 
eleven influenza virus proteins namely NS1, PB1-F2 and M2 have been 
implicated in manipulation of  apoptosis (Herold, Ludwig, Pleschka, & Wolff, 
2012). NS1 is an important factor that promotes viral gene expression by 
inhibiting the Type 1 interferon activity of the host (Hale, Randall, Ortin, & 
Jackson, 2008; Wolff & Ludwig, 2009). It was observed that delNS1 mutants 
cause more apoptosis compared to the WT suggesting that NS1 extends viral 
lifetime in the cell (Zhirnov, Konakova, Wolff, & Klenk, 2002). These effects 
were partially attributed due to the anti-interferon activity of the protein 
because they were not observed in IFN deficient cells (Schultz-Cherry, 
Dybdahl-Sissoko, Neumann, Kawaoka, & Hinshaw, 2001). NS1 also interacts 
with the p85 subunit of the PI3K to activate the pro-survival pathways 
(Ehrhardt, Wolff, & Ludwig, 2007; Ehrhardt et al., 2007) and suppresses 
protein kinase R (PKR) activity to inhibit DISC formation and hence apoptosis 
(Balachandran et al., 2000). 
PB1-F2, contrary to NS1 is a pro-apoptotic protein contributing to viral 
pathogenicity (W. Chen, et al., 2001). It interacts with mitochondrial proteins 
like adenine nucleotide translocase 3 and voltage-dependent anion channel 
(VDAC) leading to MOMP (McAuley et al., 2010; Zamarin, Garcia-Sastre, 
Xiao, Wang, & Palese, 2005). Strain dependant differences have been observed 
in case of PB1-F2 with respect to viral replication (Le Goffic et al., 2010), 
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polymerase modulation (Mazur et al., 2008), and mitochondrial localization (C. 
J. Chen et al., 2010). 
The ion channel protein M2 inhibits macroautophagy which is important for 
cell survival and also binds to beclin-1 suggesting that it contributes to the 
induction of apoptosis by influenza virus (Gannage et al., 2009). 
 
Figure 1.9 Model of Influenza induced Apoptosis. 
(A) In the early stages of infection NS1 interacts with p85 subunit of PI3K and 
activates Akt pathway by phosphorylation which regulates the downstream 
pro-apoptotic factors like caspases, BAD and GSK3β and suppress apoptosis in 
the early stages.(B and C) In the later stages the virus induces NF-κB 
expression by activating IKK which phosphorylaties the inhibitor of κB alpha 
(IκBα) and promotes its localisation into the nucleus.NF-κB activation leads to 
the expression of pro-apoptotic factors like TRAIL and FasLwhich induce 




As shown in the figure, the apoptotic pathways in the later stages are beneficial 
for the viruses. These pathways promote viral replication and propagation. In 
caspase deficient cell line MCF-7 the replication efficiency of IV was very low 
and was boosted upon ectopic expression of caspase-3 (Wurzer et al., 2003). 
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Overexpressions of anti-apoptotic protein Bcl-2 also lead to decreased virus 
titers (Olsen, Kehren, Dybdahl-Sissoko, & Hinshaw, 1996). Mechanistically, 
this observation was due to the retention of vRNP complexes in the nucleus. 
The transport of RNPs can be either via the caspase dependent passive 
transport machinery or Crm-1 dependant active transport as observed by using 
caspase and Crm-1 inhibitors (Elton et al., 2001; Faleiro & Lazebnik, 2000). 
These findings can be merged to develop a model where the vRNP is 
transported via the active machinery in the initial stages but once the caspases 
are activated they cleave the active transport proteins and then the transport is 
through the widened nuclear pores created by caspase due to the degradation of 
nuclear pore proteins (Faleiro & Lazebnik, 2000; Herold, et al., 2012; Kramer 
et al., 2008). Also, upon infection the death ligands TRAIL and FasL are 
upregulated in a NF-κB dependant manner and hence regulate virus 
propagation through apoptosis (Wurzer et al., 2004). 
1.5. Aims of the study 
 
This project aims to characterize the role of ANXA1 in TLR7 signalling and 




ANXA1 might plays a role in TLR 7 signalling and influence influenza virus 






Chapter 2 Materials and 
Methods 
 




10X PBS buffer was obtained from 1st base (Singapore). The stock comprised 
of 137mM NaCl, 2.7mM KCl and 10mM phosphate buffer. It was diluted to 
1X using 9 parts of sterile water. pH was adjusted to 7.2-7.4 and the solution 
was autoclaved. 
2.1.2. FACS buffer 
 
FACS buffer consists of 1X PBS supplemented with 1% FBS and 2mM 
EDTA. 0.05% sodium azide was added as a preservative to allow usage under 
non sterile conditions. 
2.1.3. Red Blood Cell (RBC) Lysis Buffer 
 
10X RBC lysis buffer was prepared by dissolving 8.3g Ammonium Chloride, 
0.84g Sodium Bicarbonate and 0.03g EDTA in water, the pH adjusted to 7.4 
the solution was then filter sterilized using 0.22um filter (Sartorius,Singapore) 
and volume was made up to 100ml. For use as a 1X solution, the 10X stock 





2.1.4. Wash buffer for Western Blotting (TBST) 
 
Wash buffer for Western Blotting was 1X Tris-Buffered Saline (TBS) 
supplemented with 0.5% v/v Tween-20, pH adjusted to 7.2 to 7.4. 
 
2.1.5. Buffer for ELISA 
 
Wash buffer for ELISA was 1X PBS with 0.5% v/v Tween-20, pH adjusted to 
7.2 to 7.4. Blocking buffer was 1X PBS with 1% w/v BSA, unless or otherwise 
stated by the ELISA kit. 
 
2.1.6. Complete DMEM for cell culture 
 
Complete DMEM was prepared using Dulbecco’s Modified Eagle Medium with L-
Glutamine, 4.5g/L D-glucose and sodium bicarbonate (Sigma,Singapore), 
supplemented with 10% heat-inactivated Fetal Bovine Serum (Biowest, France) 
and 1% Pencillin-Streptomycin solution ( Hyclone, USA). 
 
2.1.7. Complete F-12K media for cell culture 
 
Nutrient Mixture F-12 Ham Kaighn's Modification (Sigma, USA) with L- 
Glutamine and sodium bicarbonate was supplemented with 10% heat-
inactivated Fetal Bovine Serum (Biowest, France) and 1% Pencillin-





2.1.8 Plain DMEM at 2X concentration 
 
DMEM powder with L-Glutamine and 4.5g/L D-Glucose (Sigma, Singapore) 
was dissolved in half the recommended volume of sterile water. 3.7g/L of 
Sodium bicarbonate (Sigma, Singapore) was added. The pH of the solution was 
adjusted to 7.4 and supplemented with 2% v/v Non-essential amino acids 
(Sigma, Singapore), as well as 1% Penicillin-Streptomycin (Hylone, 
Singapore) before filter sterilization through a 0.22μm filter (Nalgene, USA). 
 
2.2. Cell Culture 
 
2.2.1. Cell Lines 
 
The human epithelial lung cancer cell line A549 (CCL-185, ATCC, USA) was 
cultured in complete F-12K media (Sigma, Singapore). Macrophage Colony 
Stimulating Factor (M-CSF) producing L929 cells were generously provided 
by Dr. Sylvie Alonso and were cultured in complete DMEM 
(Sigma,Singapore) media. All cell lines and primary cells were grown at 37ºC 
in a humidified 5% CO2 incubator (Thermo Scientific, Singapore). 
2.2.2. Preparation of L929 Conditioned Media 
 
L929 cells were split from one T-75 flask into five T-75 flasks when it was 
almost 90% confluent, using trypsin (Hycone ,USA). When these five T-75 
flasks were confluent in about approximately 60hrs, they were trypsinized and 
seeded equally into thirteen T-175 flasks, each with 50 ml of complete DMEM. 
After these flasks became confluent they were incubated for additional two 
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days to condition the media. The supernatant of all 13 T-175 flasks was filtered 
and stored at -20oC for further use. 
2.2.3. Generation of Bone Marrow Derived Macrophages (BMMOs) 
 
Six to ten week old Balb/c mice were used for the extraction of Bone marrow. 
Mice were sacrificed and their hind limbs were obtained. The bones were 
cleared of the flesh using a gauze cloth/ tissue and were disinfected by dipping 
in 70% ethanol .They were then transferred to a dish containing DMEM media. 
The two ends of each bone were cut so that a 27G needle can pass through it, 
flushing the bone marrow out into a 50 ml Falcon tube through a 70 μm cell 
strainer (BD, U.S.A.) placed on top of the tube. Tubes were then spun at 280g 
for 10 mins at 4°C. Cell pellet was resuspended in 1 ml of red blood cell lysis 
buffer and incubated on ice for 5 mins. 5 ml of full DMEM was added to stop 
the lysis and the cells were then spun at 2000 rpm for 5 mins. They were then 
counted and seeded with 20% L929 conditioned media (L cell media), and 
incubated for seven days. The media was topped up on day 3 to replenish the 
MCSF required for differentiation. 
2.2.4. Generation of Bone Marrow Dendritic Cells (BMDCs) 
 
Bone marrow cells were obtained as described above for BMMOs. After RBC 
lysis cells cells were resuspended in complete RPMI media supplemented with 
non-essential amino acids (1X) (Sigma, Singapore), vitamins (1X) (Sigma, 
Singapore) and GM-CSF derieved from supernatant of J558L cell line (a kind 
gift from Dr. Veronique Angeli) at a  concentration of 2x106/ml. On day two, 
the dish was topped up with equal amount of media already present in the dish. 
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Cells were pelleted and media was completely replaced on day four and 
replenished with fresh media. Cells were plated again at the same concentration 
as mentioned above and were used on day seven. 
2.2.5. Isolation of splenic cells  
 
Spleens were isolated from the mice and homogenized. The cell suspension 
was passed through a 70µm strainer to obtain a single cell suspension. This cell 
suspension was used for the CFSE staining. For western blot B cells were 
purified using Easysep mouse B cell enrichment kit (STEMCELL 
technologies, Singapore). All cells were cultured in complete DMEM.  
2.2.6. Lung cell culture 
 
Lungs were harvested from euthanized mice and excised into small pieces in 
1mg/ml Collagenase Type A (Roche Diagnostics, Singapore) and digested for 
45 min at 370C. The suspension was homogenized using a Pasteur pipette after 
20 mins of digestion. The digested lungs were physically disrupted into a 
single cell suspension by passing through a 70µm cell strainer (Fischer 
Scientific, Singapore). Single cell suspensions were washed with F-12K media 
to remove collagenase and were plated into 10 cm diameter plate. The media 
was changed after three days. The cells were ready to use after 7 days. 
2.2.7. Cell staining with CFSE and proliferation analysis 
 
Splenic cells were obtained as described earlier. The cells were then stained 
with 5µM CFSE dye (Sigma, Singapore) for 30 mins at 37ºC. The cells were 
washed twice and plated in complete DMEM. They was then treated with 
1µg/ml of R848 (Invivogen, USA). Cells were harvested after 72 hrs, data was 
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acquired using CyAn analyzer (Beckman Coulter, Singapore) and analysis was 
done using FlowJo software (TreeStar, USA). 
2.2.8. Thymidine Assay 
 
Splenocytes (2x105) were treated with various concentrations of R848 for 72 
hrs and thymidine at a concentration of 0.5milliCurie was added 18 hrs before 
harvesting cells. The readings were taken using a scintillation counter. 
2.2.9. Transfection 
 
Over-expression and knock down of ANXA1 in A549 cells was done using 
Turbofect transfection reagent (Fermentas, USA). DNA to reagent ratio was 
maintained at 1:2. 100,000 cells were seeded in a 24 well plate the day before 
transfection antibiotic free media. Transfection was performed according to 
manufacturer’s instructions. 500ng of DNA was transfected per well. Media 
containing the transfection complexes was changed to complete media 6 hrs 
after transfection. Cells were used for subsequent experiments 24-36hrs post 
transfection. 
2.3. Mice  
 
Balb/c mice 6-10 weeks old were purchased from Centre for Animal Resources 
at the National University of Singapore. ANXA1-/- mice were a kind gift from 
Prof. Roderick Flower. Mice were housed and bred in pathogen free conditions 
.in compliance with the Institutional Animal Care and Use Committee 





2.3.1. Infection of mice with Influenza virus 
 
6-8 weeks old Balb/c mice were anesthetized with intraperitoneal injections of 
Ketamine, 100mg/kg and Medetomidine, 15mg/kg cocktail. (Comparative 
Medicine, NUS). Intratracheal challenge with influenza was carried out with 
500pfu of the virus in 20µl of PBS. Atipamezole (Comparative Medicine, 
NUS), 5mg/kg was administered by intraperitoneal injection to reverse the 
effects of the anaesthetic.  
2.3.2. Cellular Infiltration 
 
 Broncheoalveolar lavage (BAL) was obtained from the uninfected and 
infected mice 1,3 and 7 days post infection and was spun to separate the cells 
and lavage. The RBCs were removed using a RBC lysis buffer and cells were 
counted using a hemacytometer. These cells were then stained with CD45, 
CD11c, CD3/ CD19, Ly6-G, CD11b, CD14, F4/80 and Siglec F to determine 
the cellular composition. 
 
Target  Host  Conjugation  Source  
CD3  Rat  PerCp Cy5.5 ebioscience  
CD11b Rat  APC Cy7  eBioscience  
CD11c Hamster  PE Texas Red  eBioscience  
CD14 Rat  FITC  eBioscience 
CD19 Rat  PerCp Cy 5.5 eBioscience 
CD45 Rat  PE Cy7 BD Pharmingen  
F4/80  Hamster  APC BD Pharmingen  
Ly6G  Rat  Pacific Blue Biolegend  
Siglec F Rat  PE  BD Pharmingen  




2.3.3. Lung Histology  
 
To observe the cellular infiltration and lung damage Haematoxylin and Eosin 
(H&E) staining was performed on the lung sections from naive, 5 and 10 days 
infected mice. Essentially, lungs were isolated from the thoracic cavity after 
the mouse was euthanized, fixed in 10% neutral buffered formalin solution for 
at least 48 hours, and processed in a tissue processor (Leica Microsystems, 
Wetzler, Germany). Briefly, lungs were dehydrated in a series of ethanol 
mixtures (70% to 80% to 90% to 100%, 30 minutes each and 2 hours for 
100%), and immersed in xylene for 10.5 hours. Lungs were perfused with hot 
paraffin for 3 hours and embedded in paraffin wax. The specimens were then 
cut into 5 μm sections using a microtome (Leica Microsystems, Wetzler, 
Germany) and fixed on slides. For H&E staining, slides were deparaffinized 
with HistoClear for 10 min and rehydrated in a series of ethanol to water 
mixtures (100% to 90% to 70% to water and each for 2 minutes). The sections 
were then stained with Harris haematoxylin for 5 minutes, washed in the 
distilled water, and differentiated in 0.1% acid alcohol solution for 30 seconds. 
The sections were washed with tap water for 5 minutes and counter stained 
with Eosin for 1 minute. Subsequently, the sections were dehydrated in a series 
of ethanol solutions (70 % to 90% to 100% and each for 30 seconds) and 
immersed in HistoClear for 10 minutes. Evaluation of inflammation around 
peribronchial and perivascular areas was semi-quantitatively performed in a 
blind manner. A subjective scale (0-3) was assigned as follows: 
 0, no inflammation 
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 1.  mild, inflammatory cell infiltrate of the perivascular/peribronchiolar 
compartment 
 2. moderate, inflammatory cell infiltrate of the perivascular/peribronchiolar 
space with modest extension into the alveolar parenchyma  
3. severe, inflammatory cell infiltrate of the perivascular/peribronchiolar space 
with a greater magnitude of inflammatory foci found in the alveolar 
parenchyma. The blinded scoring was kindly done by Dr. Ben Yan, 
Pathologist, KK Hospital, Singapore.  
 
2.4 Influenza Virus Culture and Infection 
 
2.4.1. Virus culture in chicken Embryos 
 
Nine to ten day old embryonated chicken eggs were purchased from Bestar 
Laboratories (Singapore). After locating the air cell and marking out the large 
blood vessels, a 21G needle was used to puncture the egg shell. Using a fine 
needle, 10 HAU of Influenza A/PR8/34 (H1N1) stock kindly provided by Prof. 
Vincent Chow, diluted in PBS buffer was carefully injected into the allantoic 
cavity through the hole. The hole was then sealed with melted wax to preserve 
sterility. Eggs were then kept in a 37oC incubator without CO2. They were 
candled every day for the viability of the embryos. After 2 to 3 days, the 
embryos were culled by placing the eggs at 4oC for 4 hours after which the egg 
was broken through the air cell and the allatoic fluid was harvested. The 
allantoic fluid was clarified by spinning at 3000 g before it was concentrated 
and stored at -80oC. 
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2.4.2 Concentration of Influenza virus 
 
The clarified allantoic fluid containing the virus obtained from the eggs was 
poured into a Vivaspin 20 centrifugal concentrator with a membrane pore size 
of 100,000kDa molecular weight cut-off (Sartorius AG, Germany). The 
concentrator was centrifuged at 3000g at 4oC, stopping at intervals of 30 mins 
to resuspend the top fractions to permit a better flow rate and to discard the 
flowthrough in the bottom fraction. The top fractions were then pooled and 
quantified using plaque assays on MDCK cells. 
2.4.3 Plaque forming assay 
 
 MDCK cells were seeded at a density of 2.5 x 105 cells/well in a 24-well plate 
and cultured in complete DMEM until fully confluent and the spaces between 
cells are barely distinguishable. Immediately before infection, the media was 
withdrawn and the cells were washed once with PBS to remove any traces of 
serum which may affect the ability of the virus to bind to the cells. The virus 
was then serially diluted 10-folds in serum-free DMEM and overlaid on 
MDCK cells for 1 hour at 37oC to allow the virus to adsorb onto the cells. The 
volume of the inoculum was kept small, typically 250μl per well so as to 
ensure maximal adsorption of the virus onto the cells. During the incubation 
period, a 2% agarose solution in sterile water was prepared and kept in molten 
state by incubating in a water bath at 47oC. At the same time, 2X DMEM was 
warmed to 37oC and TPCK Trypsin was added to a final concentration of 
4μg/ml. After one hour the molten 2% agarose was mixed with an equal 
volume of 2X DMEM to obtain a 1X DMEM agarose solution. The virus 
inoculums were quickly removed and cells were overlaid with the DMEM-
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agarose. Plates were incubated for 3 days at 37oC to allow the formation of 
plaques. To visualise plaques on the third day, 0.5 to 1ml of PBS was added on 
top of the agarose layer to facilitate removal of the agarose overlay and a bent 
needle was used to gently dig out the agarose layer above the cells. Care must 
be taken to avoid scratching the bottom of the plate. Plaques were visualised by 
adding crystal violet solution and incubating for at least 5 minutes. Excess stain 
was removed by washing the plates with water. 
2.4.4 Infection of cells with Influenza virus 
 
For infection A549 cells were plated in complete F-12K media one day before. 
The media was aspirated and the monolayer was washed with PBS. The 
inoculum containing virus at specified MOI in serum free medium was 
incubated with cells for 1hr following which it was aspirated and the cells were 
washed with PBS. For viral titer assay F-12K+ 2% FBS + 1µg/ml TPCK 
trypsin was added. For all other experiments complete F-12K was added. 
2.5 Measurement of Cytokines  
 
Levels of cytokines : IL-6, IL-12p70, IL-10, IL-1β, TNFα, TGF-β IFNα , IFNβ 
and IFN-g  were detected using the commercially available Ebioscience Ready-
Set-go® kits according to manufacturer’s instructions. Briefly, the capture 
antibody was diluted to the working concentration in the coating buffer and a 
96-well maxisorp plate (NUNC) was coated with 50µL per well of the diluted 
capture antibody. The plate was then sealed and incubated at 4ºC overnight. 
Next day, each well was aspirated and then washed with the ELISA wash 
buffer three times. After the last wash, inverting the plate and blotting it on 
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clean paper towels removed any remaining wash buffer.  The plate was then 
blocked by adding 100µl of blocking buffer and incubating for 1h at room 
temperature. It was then washed as mentioned earlier. 50µL of sample or 
standard in the blocking buffer was added to the wells. The plates were then 
sealed and incubated for 2h at room temperature or O/N at 4ºC. After the 
incubation plate was washed and detection antibody was added for 1 hr. Plate 
was then washed and a working dilution of Streptavidin-HRP (50µL) was 
added to each well. The plate was covered and incubated for 30mins at room 
temperature after which it was washed and 50µl of TMB substrate was added 
to each well. After incubation for color development of 15 mins 50µl of stop 
solution 2N H2SO4 was added to each well. The absorbance was then measured 
at 450nm. 
2.6 Western Blot 
 
2.6.1. Protein lysis 
 
The culture medium was aspirated and cell monolayer was washed once with 
1X PBS. Cells were scraped in ice cold PBS and pelleted by spinning at 
2000rpm for 10mins. They were then lysed using the 1X RIPA buffer 
consisting of 50mM sodium chloride (NaCl), 0.1% NP-40, 0.5% sodium 
deoxycholate (C24H39O4Na), 0.1% SDS and 50mM Tris-HCl supplemented 
with protease inhibitor (Thermo Scientific Halt Protease inhibitor).Cells were 
left to stand on ice for 30 minutes and tapped intermittently before being 
centrifuged at 12000 rpm for 15 minutes. The supernatant was carefully 
removed and stored at -80°C. 
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2.6.2. Protein Concentration Quantification 
 
Protein concentrations were estimated using 1X Bradford’s reagent (BioRad 
Protein Assay) and BSA standards (Thermo Scientific Pierce). Absorbance was 
measured using a BioRad spectrophotometer at 595nm. 
2.6.3 Blotting  
 
30-50 μg of proteins per samples were loaded onto a 10%  or 12% SDS-PAGE 
gel which was run in 1X Running buffer (0.025 M Tris, 0.192 M Glycine and 
0.1% SDS) at 80 V for 20 minutes (stacking phase) and 125 V for 90 minutes 
(resolving phase).Wet transfer was performed using 1X Transfer buffer (20% 
Methanol, 25 mM Tris and 192 mM Glycine) onto a nitrocellulose membrane 
(BioRad) for 60 minutes at 0.35 mA on ice. Membranes were stained with 
Ponceau S (0.1% w/v in 1% acetic acid) to check for successful transfer. 
Membranes were blocked using 5% skimmed milk (Anlene, Fonterra) for 30 
minutes at room temperature on an orbital shaker (80 rpm). They were then 
washed twice with 1X TBST (1X TBS + 0.1% Tween-20) for 2-3 minutes 
each. Incubation with primary antibodies was performed overnight at 4°C on 
an orbital shaker (table of antibodies used is given below). Membranes were 
washed twice with 1X TBST for 5 minutes each followed by incubation with 
secondary antibodies for 60 minutes at room temperature on the shaker. 
Membranes were washed thrice with 1X TBST for 3-5 minutes each. 
Chemiluminescent detection was performed by exposure to SuperSignal West 
Pico Chemiluminescent Subtrate (Thermo Scientific). This was followed by 
exposure to CL-Xposure (Thermo Scientific) films in an autoradiography 
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cassette (Amersham Hypercassette™) until protein bands could be visualised 





Primary Antibody Dilution Company 
 Rabbit Annexin A1 1:000 Cell Signaling 
Techonlogy Inc 
(Danvers, MA, U.S.A) 
Rabbit  p-Akt (s473) 1:1000 Cell Signaling 
Techonlogy Inc 
(Danvers, MA, U.S.A) 
Rabbit  total Akt 1:1000 Cell Signaling 
Techonlogy Inc 
(Danvers, MA, U.S.A) 
Rabbit Cleaved 
Caspase 3 
1:1000 Cell Signaling 
Techonlogy Inc 
(Danvers, MA, U.S.A) 
Rabbit Caspase 3 1:1000 Cell Signaling 
Techonlogy Inc 
(Danvers, MA, U.S.A) 
Rabbit Cleaved 
Caspase 7 
1:1000 Cell Signaling 
Techonlogy Inc 
(Danvers, MA, U.S.A) 
Rabbit Caspase 7 1:1000 Cell Signaling 
Techonlogy Inc 
(Danvers, MA, U.S.A) 
Rabbit Cleaved PARP  1:1000 Cell Signaling 
Techonlogy Inc 
(Danvers, MA, U.S.A) 
Rabbit PARP 1:1000 Cell Signaling 
Techonlogy Inc 
(Danvers, MA, U.S.A) 
Mouse Tubulin 1:2000 Sigma-Aldrich Co (St. 
Louis, MO, U.S.A.) 




2.7.  Real Time PCR 
 
2.7.1. RNA Isolation from cells 
 
Total RNA was isolated using the phenol-chloroform extraction method. Cells 
were lysed using Omics MaestroZolTM RNA plus extraction reagent (Omics 
Biotechnology). The homogenised samples were incubated at room 
temperature for 5 minutes followed by addition of 0.2 ml of chloroform 
(Sigma-Aldrich,) per ml of MaestroZol reagent. Samples were mixed by 
inverting a few times and incubated at room temperature for 10 minutes. They 
were then centrifuged at 12,000 g for 15 minutes at 4°C. The clear aqueous 
layer was transferred to a new, clean 1.5 ml Eppendorf tube. 0.5 ml 
isopropanol per ml MaestroZol was added to the clear aqueous layer and mixed 
well. The samples were incubated at room temperature for 10 minutes and 
centrifuged at 12,000 g for 10 minutes at 4°C. The RNA pellet was washed 
with at least 1 ml of 75% ethanol. The samples were mixed by vortexing and 
centrifuged at 7500 g for 5 minutes at 4°C. Supernatant was removed and RNA 
pellets were air dried for 10 minutes at room temperature before being 
dissolved in nuclease free water. The samples were quantitated using a 
nanodrop spectrophotometer (BioFrontier Technology). Only RNA samples 
with A260/A280 ratio of values equal to or greater than 1.8 were used and 
RNA was stored at -80°C. 
2.7.2.  RNA isolation from lungs 
 
Infected and naive mice were euthanized using CO2 and lungs were harvested 
which were then cut into small pieces and stored in RNA later (Qiagen). RNA 
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was isolated using RNAeasy kit according to manufacturer’s instructions 
(Qiagen). 
2.7.3. Viral RNA (vRNA) isolation from cell supernatant 
 
Viral RNA from culture media of infected cells was harvested using viral RNA 
extraction kit (Geneaid) according to the manufacturer’s protocol. 
 
2.7.4.  cDNA Synthesis 
 
For cDNA synthesis following mix was prepared in each of the sample tubes 
and incubated at 65°C for 5 minutes after which the tubes were immediately 
put on ice. 
Total RNA  1 µg 
Random Primers 200ng 
10mM dNTPs 1µl 
Nuclease free water Upto 12µl 
Table 2.3 cDNA synthesis initial reaction mix 
 
After the initial reaction the following master mix was prepared and added to   
each sample. Tubes were spun and incubated at 25°C for 2 mins. 
5X M-MLV RT buffer 4µl 
RNAsin(40U/ml) 0.25µl 
Nuclease free water To make 
Final volume 
19µl 




Finally 1ul of reverse transcriptase enzyme was added, and the mixture was 
incubated at 25°C for 10mins , followed by 42°C for 60 mins and 70°C for 15 
mins.  cDNA was stored at -20°C. 
 
2.7.5.  Real time PCR 
 
GoTaq® qpCR master mix (Promega) was used and a master reaction was 
prepared. For each reaction  
 
2X GoTaq® qpCR master mix 10 μl 
10uM forward primer 0.4 μl 
10uM reverse primer 0.4 μl 
cDNA template (5 ng) 1.0 μl 
Nuclease-free water 7.4 μl 
Table 2.5 qPCR reaction mix 
The following PCR protocol was used: 
50°C, 2 minutes, 
95°C, 10 minutes, 
40 cycles of 95°C, 15 seconds and 60°C, 1 minute 
50°C, 15 seconds 
60°C, 1 minute, 
95°C, 30 seconds, 
60°C, 15 seconds 
Melting curve analysis was performed after that at 95°C for 1 minute and 55°C 
for 1 minute. The ABI 7500 real-time PCR system (Applied Biosystems) was 
used for analysis. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or 
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beta-actin was used as the endogenous control. Relative expression was 
computed by ΔΔCt a method. Primer sequence list is provided below. 
 
Primer Sequence Company 
Mouse IL-6 
(Forward) 




























5’-TTG GTT TGG GAG GAA AGG G-3’ 1st Base 
(Singapore)  
Mouse IFN α 
(Forward) 
5’-TGTCTGATGCAGCAGGTG-3’ 1st Base 
(Singapore)  
Mouse IFN α 
(Reverse) 
5’-AAGACAGGGCTCTCCAGA-3’ 1st Base 
(Singapore)  
Mouse IFN β 
(Forward) 
5’-GGCCGACTTCAAGATCCCTAT-3’ 1st Base 
(Singapore)  
Mouse IFN β 
(Reverse) 










5’-TGCATCAAACTGAGCTGGAG-3’ 1st Base 
(Singapore) 
Viral M gene 
(Forward) 
5’-GGACTGCAGCGTTAGACGCTT-3’ 1st Base 
(Singapore) 
  
Viral M gene 
(Reverse) 








5’-TTCACCATTGCCTTCTCTTC-3’ 1st Base 
(Singapore) 
  
Viral M gene 
(Reverse) 










5’-CCACACCTAGCAACCAGAAGTTAG-3’ 1st Base 
(Singapore) 
Table 2.6 List of primers 
     
2.8.  Luciferase Assay 
 
For the luciferase assay 100,000 A549 cells were plated in a 24 well plate one 
day before transfection. The following day 200 ng of NF-κB luciferase reporter 
plasmid and 10 pg of Renilla plasmid along with scrambled or ANXA1 shRNA 
or ANXA1-V5 tagged plasmids were transfected. 24hrs later cells were 
infected with Influenza virus at a MOI of 1 for 12hrs. Cells were then lysed in 
120µl of passive lysis buffer and Luciferase activity was determined using 
Dual-Luciferase® Reporter Assay System (Promega) as per manufacturer’s 
protocol. Luciferase activity was measured using a spectrophotometer (Perkin 
Elmer VICTOR3™ V Multilabel Counter Model 1420). 
2.9.  Caspase 3/7 assay 
 
10,000 cells were plated in a 96 well plate one day before transfection with 
control or ANXA1 siRNA . 24 hours post transfection, cells were infected with 
Influenza virus at a MOI of 1 and were grown for 48 hrs before apoptosis was 
assessed by Caspase-Glo® 3/7 Assay Systems (Promega). Substrate was added 
to the well containing media in the ratio 1:1. Luminiscence was measured 
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Unpaired sets of data were compared using unpaired Student’s t-test (two-
tailed). In all cases, p<0.05 was accepted as statistically significant. Survival 




Chapter 3 Results 
 
 
Annexins have been known to be involved in infectious diseases such as 
Tuberculosis (Gan, et al., 2008), HIV (Ryzhova, et al., 2006) and Hepatitis C 
(Backes, et al., 2010). The presence of ANXA1 on the phagosomal membrane 
seems to be functionally important in macrophages and neutrophils. Rapid 
translocation of ANXA1 to the phagosome membrane has been observed 
during the phagocytosis of non-pathogenic or killed bacteria (Harricane, Caron, 
Porte, & Liautard, 1996; Kaufman, Leto, & Levy, 1996), and macrophages 
from ANXA1-knockout mice decreases phagocytosis of non-opsonised 
zymosan (Yona, et al., 2006). ANXA1 is also involved in TLR-mediated 
production of pro- or anti-inflammatory cytokines (Y. H. Yang, Aeberli, 
Dacumos, Xue, & Morand, 2009; Y. H. Yang, et al., 2006; Yona, et al., 2006) 
indicating that ANXA1 may be crucial regulator for the balance between pro- 
and anti-inflammatory cytokines. Dendritic cells obtained from ANXA1 KO 
mice exhibit higher maturation and hence lower phagocytocis and migratory 
potential. The activation of NF-κB, ERK1/2 and Akt is also decreased in 
ANXA1 KO dendritic cells (Huggins, et al., 2009). It also regulates T-cell 
activation and differentiation (D'Acquisto et al., 2007).  More recently, we 
have shown that ANXA1 is a binding partner of IKK complex and keeps NF-
κB constitutively active (Bist, et al., 2011). Our recent publication also 
revealed that ANXA1 plays a critical role in TLR3-mediated IFN regulation by 
binding to TBK-1 and regulating IRF3 phosphorylation and its translocation to 
the nucleus. Having observed an important role of ANXA1 in TLR3 signalling, 
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in this project we wished to characterize its role in TLR7 signalling using 
artificial ligands and in influenza virus infection since single stranded (ss)RNA 
viruses are the natural ligands of TLR7. 
 
3.1.  Endogenous levels of TLR7 in WT and ANXA1-/- are similar in both 
BMMOs and DCs 
 
TLRs act as the first line defense mechanism against microbial infections by 
playing a pivotal role in the recognition of bacteria and viruses. Aberrant 
expression of these pathways has serious consequences in autoimmune 
diseases and cancer. As mentioned above, ANXA1 plays an important role in 
TLR3 mediated production of IFN-β and CXCL10 by associating with TBK-1 
through its C-terminal (Bist, et al., 2013). TLR7 is one of the most important 
PRRs for ssRNA viruses. Efficiency of detection of ssRNA or 
imidazoquinoline compounds depend on TLR7 gene expression (S. Huang, 
Wei, & Yun, 2009). In order to investigate if antigen presenting cells from 
ANXA1-/- have an inherent advantage in recognition of ligands we determined 
the endogenous levels of TLR7 in bone marrow macrophages (BMMOs) 
(Figure 3.1A) and bone marrow dendritic cells (BMDCs) (Figure 3.1B). 









Figure 3.1 Endogenous TLR7 levels are similar in both WT and ANXA1-/- 
RNA from WT and ANXA1-/-  (A) BMMOs and (B) DCs was extracted and 
endogenous levels  of TLR7 were determined using qPCR. Results are 
representative of two independent experiments expressed as mean±SD. 
 
 
3.2.  R848 efficiently activates TLR7 pathway  
 
TLR7 recognizes ssRNAs as their natural ligand and also small synthetic 
molecules such as imidazoquinolines and nucleoside. BMMOs from WT mice 
were treated with CL264 (1µg/ml), Gardiquimod (1µg/ml), Imiquinod (R837) 
(1µg/ml) and Resiquimod (R848) (300ng/ml) and activation was assessed by 
production of pro-inflammatory cytokines IL-6 and IL-12p40 (Figure 3.2). 
The maximum production for both cytokines was observed in the case of R848 
compared to the other three agonists, even at a very low dose. Use of R848 has 
also been widely reported in the literature therefore we used R848 for all 










Figure 3.2 R848 stimulates maximum production of cytokines. 
BMMOs were treated with different TLR7 ligands, CL264 (1µg/ml), 
Gardiquimod (1µg/ml), Imiquinod (R837) (1µg/ml) and Resiquimod (R848) 
(300ng/ml) for 24 hrs and pro-inflammatory cytokines (A) IL-6 and (B) IL-
12p40 were measured to detect the efficacy of the ligands. Results are 










3.3. ANXA1 is selectively required for the production of pro-inflammatory 
cytokines 
 
TLR activation triggers the production of pro and anti-inflammatory cytokines, 
and these cytokines play an important role in shaping the adaptive immune 
response. We therefore compared the expression of the proinflammatory 
cytokines, type I interferons and the transcription factors that regulate them 
from WT and ANXA1-/- mice after stimulation with R848 in BMMOs and 
BMDC. Since the regulation of these cytokines begin at transcriptional level 
post treatment, we first determined the RNA levels for IL-6, IL-12p40, TNF-α, 
IFNα, IFNβ and the regulators of type I interferons  IRF7 and IRF5 for both 
cell types, followed by ELISA for IL-6, IL-12p40 and TNF-α to verify if the 
differences observed at RNA levels can be seen post-translationally. In case of 
BMMOs, IL-6, IL-12p40, IFNβ and IRF7  RNA expression was impaired in 
ANXA1-/- cells while TNF-α, IFNα  and IRF5 were not affected (Figure 3.3). 
These differences in IL-6 and IL-12p40 were observed in protein levels as 
well, as shown by ELISA (Figure 3.4).  
Surprisingly, cytokine expression in ANXA1-/- BMDCs was different to that of 
BMMO. All the genes except IRF5 (Figures 3.5 and 3.6) were upregulated in 
ANXA1-/- cells. A discrepancy was observed in the levels of IL-12p40 where 
the RNA expression levels were higher in ANXA1-/- BMDC (Figure 3.5B) 
whereas the protein levels were lower in these cells. These results indicate a 
selective requirement of ANXA1 in TLR7-mediated signalling pathway and it 
differentially regulates the production of inflammatory cytokines depending 




Figure 3.3 Pro-inflammatory cytokines and Type I interferon expression is 
downregulated in ANXA1-/- BMMOs. 
BMMOs were treated with 300ng/ml of R848 and were harvested 2,4 and 8 hrs 
later. RNA was collected and qPCR was done for (A) IL-6, (B) IL-12p40, (C) 
TNFα, (D) IFNα, (E) IFNβ, (F) IRF7 and (G) IRF5. Data is represented as 
mean ±SEM from three independent experiments and analysed using two-way 





Figure 3.4 Pro-inflammatory cytokine production is downregulated in 
ANXA1-/- BMMOs. 
BMMOs were treated with 300ng/ml of R848 and supernatants were harvested 
24hrs later. ELISA was performed for (A) IL-6, (B) IL-12p40 and (C) TNFα. 
Data is representative of three independent experiments expressed as 









Figure 3.5 Pro-inflammatory cytokines and Type I interferon expression is 
upregulated in ANXA1-/- BMDCs. 
BMDCs were treated with 300ng/ml of R848 and were harvested 2, 4 and 8 hrs 
later. RNA was collected and qPCR was done for (A) IL-6, (B) IL-12p40, (C) 
TNFα, (D) IFNα, (E)  IFNβ, (F) IRF7 and (G) IRF5. Data is represented as 








Figure 3.6 Pro-inflammatory cytokine production is upregulated in 
ANXA1-/- BMDCs. 
 BMDCs were treated with 300ng/ml of R848 and supernatants were harvested 
24hrs later. ELISA was performed for (A) IL-6, (B) IL-12p40 and (C) TNFα. 
Data is representative of three independent experiments expressed as 






3.4.  TLR dependent inflammasome activation is higher in ANXA1-/- cells  
 
 Another important pro-inflammatory cytokine is IL-1β. However, its 
production through TLRs is not direct. TLRs only act as a primary signal for 
the production of proIL-1 β and activation of few inflammasome components, 
which is cleaved by capsase 1 inflammasome upon activation by another signal 
from danger associated molecular patterns (DAMPS) leading to the production 
of mature IL-1β (Mariathasan & Monack, 2007). Though any TLR agonist can 
provide the first signal for the production of IL-1β, RNA viruses such as 
influenza virus trigger this host response via TLR7 (Ichinohe, Pang, & Iwasaki, 
2010). Therefore, we next used R848 to activate the inflammasome in WT and 
ANXA1-/- BMDC. 
To assess the effects of ANXA1 on inflammasome activation, we primed 
ANXA1-/- and WT BMMOs and BMDCs with lipopolysaccharide (LPS) (used 
as a positive control) or R848 for 16 hr in order to induce pro-IL-1β synthesis 
and stimulated with ATP to activate IL-1β maturation via inflammasome 
activation. Extracellular adenosine triphosphate (ATP) is a DAMP that is 
released at sites of cellular injury or necrosis. LPS or R848 alone was not able 
to induce IL-1β production, however cotreatment of ATP with either LPS or 
R848 resulted in IL-1β production in both WT and ANXA1-/-. Interestingly, 
ANXA1-/- cells produced more IL-1β in both cell types, indicating that 
ANXA1 deficiency amplifies ATP-driven IL-1β production with R848 or LPS 
(Figure 3.7). The results obtained for BMDCs are in conjunction with previous 
cytokine production results that seem to suggest that TLR7 signalling is more 








Figure 3.7 Increased IL-1β production in ANXA1-/- BMDCs and BMMOs. 
BMDCs and BMMOs were isolated from ANXA1-/-and WT mice, and 
subsequently primed either with LPS or R848 for 16 h. Thereafter, the cells 
were stimulated with ATP for another 4 h. IL-1β release was assessed by 
ELISA. Data is representative of three independent experiments expressed as 








3.5. ANXA1-deficient splenic B cells exhibit increased activation and 
proliferation. 
 
Having established a phenotype for involvement of ANXA1 in cytokine 
production involving TLR7 in innate immune cells, we next studied its role in 
adaptive immune cells. In addition to the cytokine secretion by macrophages 
and dendritic cells, imidazoquinolines also possess activation and proliferation 
potential for B cells (Bishop et al., 2000). To demonstrate the involvement of 
ANXA1 in proliferative responses, splenocytes were obtained from 6-8 wk-old 
ANXA1-/- and WT mice. These were then stimulated with R848 and CpGB (a 
very potent proliferation inducer of B cells) followed by staining with cell 
specific markers and CFSE to determine proliferating cells. Proliferation was 
observed in B220+ cells in both WT and ANXA1-/- cells, suggesting that B cells 
proliferated in response to TLR stimulation. Interestingly, more proliferation 
was observed in ANXA1-/- as compared to WT in both R848 (Figure 3.8B) 
and CpGB (Figure 3.8C). Each peak represents one cell division. ANXA1-/- 
cells undergo 3 and 5 cell divisions compared to WT which undergo 2 and 3 
cell divisions with R848 and CpGB respectively. Quantification was done by 
calculating % proliferating cells starting from the second peak (Figure 
3.8D&E). For both the agonists used ANXA1-/- cells exhibited higher 
proliferation compared to the WT. To confirm this finding, thymidine 
incorporation assay was performed in isolated splenic B cells which again 
demonstrated higher proliferation in the ANXA1-/- cells when treated with 
various doses of R848 (Figure 3.8F). These results indicate that ANXA1 may 
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Figure 3.8 ANXA1 deficient B cells exhibit increased proliferation 
compared to WT. 
Spenocytes were isolated and stained with CFSE followed by treatment with 
1µg/ml of R848 or 1μM CpGB. (A) B cell were identified by FSC/SSC and 
B220. (B&C) CFSE analysis shows multiple peaks upon stimulation with R848 
and CpGB, representing proliferation. (D&E) Quantification of proliferation 
was done was analyzing %proliferation after treatment. (F)  Splenocytes were 
treated with various doses of R848. 31H was added 16hrs prior to the 
measurement at 72 hrs. Data is represented as mean ±SEM from three 










Since B cells are converted to antibody producing plasma cells during 
infection, we investigated the numbers of plasma cells induced during 
proliferation by staining the cells with CD138. No significant differences were 
detected in response to the R848 in WT and ANXA1-/- cells (data not shown).  
 
We next investigated R848-induced activation of splenic B cells from WT and 
ANXA1-/- mice using flow cytometry. CD86 and CD69 are the early activation 
markers present on a wide variety of cell types including B cells. Expression 
levels of these two co-stimulatory molecules were higher in ANXA1-/- cells as 


















Figure 3.9 ANXA1 deficient B cells exhibit increased activation. 
Spenocytes were isolated and treated with various doses of R848 for 24hrs (A) 
B cells were gated based on lymphocyte forward and side scatter, followed by 
B220 positivity. (B) B cells were analysed for activation markers CD69 and 
CD86. Red and green lines represent WT control and treated respectively while 
orange and blue represent ANXA1-/- control and treated. (C) Activation was 












Upon encountering pathogens, stimulation of TLRs induce signaling events 
that culminate in the activation of transcription factors needed for cytokine 
production and up-regulation of costimulatory molecules (Beutler, 2009). The 
serine-threonine protein kinase Akt mediates many of the downstream effects 
of PI3K and consequently plays a central role in cell proliferation and survival. 
Akt kinase is activated by phosphorylation of Ser 473. Thus, we evaluated Akt 
activation in splenic B cells. WT and ANXA1-/-  B cells were stimulated with 
300 ng/ml R848 at different time points, and western blot was conducted. 
Notably, high levels of basal Akt phosphoylation was detected in the ANXA1-/- 
B cells as compared to WT which increased upon stimulation (Figure 3.10). 
Akt phosphorylation was time dependent in WT, however sustained activation 
was observed in ANXA1-/- cells. This suggests that ANXA1 might regulate 














Figure 3.10 ANXA1-/- B cells display enhanced PI3K/Akt signalling in 
response to R848. 
(A) B cells were stimulated with 300 ng/ml R848 for the indicated time points, 
followed by Western blot analysis using phospho-Akt  (p) antibody. Blots were 
stripped and reprobed with anti-Akt1. (B) Quantification of pAKT with respect 

































3.6. ANXA1 deficient dendritic cells exhibit higher production of pro-
inflammatory cytokines upon virus infection. 
 
Our data so far with TLR7 ligand R848 indicates that ANXA1 affects TLR7 
signalling pathway in both innate and adaptive immune cells. To advance into 
a more clinical scenario we next infected WT and ANXA1-/- BMMOs and 
BMDCs with live and UV inactivated Influenza A/PR8/34 (H1N1) influenza 
virus (PR8) at an MOI=10, which being a single stranded virus, is a natural 
ligand for TLR7. UV inactivation preserves the virus structure but makes it 
unable to replicate. Live virus induced high levels of pro-inflammatory 
cytokines compared to UV inactivated virus in BMDCs (Figure 3.11). As 
observed with R848, ANXA1 deficient DCs produced higher levels of IL-6, 
IL-12p40 compared to WT upon treatment with both live and UV inactivated 
virus.  Levels of cytokines observed in BMMOs were almost negligible (data 
not shown).  
These results thus far obtained clearly show a difference in cytokine expression 
between WT and ANXA1-/- cells in response to TLR7 stimulation and 
influenza virus infection. However, due to the reverse trends observed between 
the innate immune cells (macrophages and DCs), it is difficult to predict 
whether ANXA1 will be a positive or negative player in influenza virus 
pathogenesis. To clarify this, we shifted our focus from the immune cells to 
epithelial cells which are the sites for virus replication and infected them with 









Figure 3.11 ANXA1 deficient dendritic cells exhibit higher production of 
pro-inflammatory cytokines upon virus infection 
BMDCs were treated with UV inactivated and live virus at a MOI=10 and 
supernatants were harvested 24hrs later. ELISA was performed for IL-6 (A), 
IL-12p40 (B) and TNFα (C). Data is representative of two independent 









3.7.  ANXA1 expression levels and its promoter activity increase upon 
virus infection in the epithelial cells in vitro. 
 
Alveolar type II epithelial cells are the major sites for viral replication therefore 
we assessed the levels of ANXA1 in A549 cell line. A549 cells were infected 
with H1N1 PR8 at a MOI of 1 for various time points. ANXA1 increases in a 
time dependent manner with maximum levels obtained 48hrs p.i. (Figure 
3.12A). Upon infection ANXA1 is cleaved into a smaller 33kDa fragment from 
24 hrs. The viability of the cells 48hrs post infection is around 40%. The 
promoter activity of ANXA1 as determined by luciferase reporter assay also 
increases three folds upon induction with influenza virus (Figure 3.12B). The 
ANXA1 luciferase plasmid was obtained from Prof. Lezarbe (Lecona et. al., 
2008). This data suggests that ANXA1 might be a virus inducible protein. 
Annexins 5 and 6 have been implicated to be playing a role influenza virus 
infection. While Annexin 5 is suggested to be involved in the entry of the virus 
(R. T. Huang, et al., 1996), Annexin 6 disrupts viral budding (Ma, et al., 2012). 











Figure 3.12 ANXA1 is upregulated and cleaved upon viral infection in 
vitro. 
(A) ANXA1 is cleaved and upregulated 24hrs onwards, post infection. Tubulin 
is used as loading control. (B) Quantification of ANXA1 western blot with 
respect to tubulin. (C) Promoter activity of ANXA1 as determined by 
luciferase reporter assay increases upon infection. Data is represented as 
mean±SEM from 3 independent experiments. *p<0.05  
 
 























3.8.   Influenza virus replication is inhibited in ANXA1 deficient epithelial 
cells. 
 
In an attempt to decipher at which step of viral propagation ANXA1 plays a 
role, A549 cells were transfected with scrambled or ANXA1-shRNA and 
infected with Influenza virus at a MOI=1 and virus titers were monitored 24 
and 48 hrs p.i. in the cells and the supernatant. This was done to determine 
whether ANXA1 plays a role in early (cells) or later (supernatant) stages of 
viral propagation. To quantify the titers in the supernatant, standard curves for 
the serial dilutions of known virus concentrations against the Ct value were 
plotted for M1 (Figure 3.13A) and NS1 (Figure 3.13B) genes. The Ct values 
obtained were fitted in the equation and corresponding virus concentrations 
were obtained. The knock down efficiency was tested using qPCR (Figure 
3.13C) and western blot (Figure 3.13D). Viral titers in the cells increased in a 
time dependant manner but the levels in ANXA1-shRNA transfected cells were 
significantly lower compared to the scrambled-shRNA transfected cells 
(Figure 3.14 A). The titers were quantified by measuring the expression of 
viral M1 and NS1 genes by qPCR. Similar data was obtained in the 
supernatants of infected cells (Figure 3.14B) which is indicative of the viral 
titers post-budding. In addition to qPCR from supernatant, plaque assay was 
also performed to assess the viral load (Figure 3.14C) and similar trend was 
observed again, where silencing of ANXA1 inhibited virus replication or 
propagation. Lower viral titers in both cells and supernatant lead us to conclude 




Figure 3.13 Standard curves for viral load quantification. 
Serial dilutions of known virus concentrations are plotted against their 
corresponding Ct values for (A) M1 and (B) NS1 genes to quantify the viral 
load.  The knock down efficiency is shown by (C)qPCR and (D) western blot. 

























































Figure 3.14 ANXA1 deficient epithelial cell exhibit lower viral titers. 
A549 cells transfected with scrambled or ANXA1-shRNA were infected with 
influenza virus. Cells (A) and supernatant (B) was harvested 12, 24 and 48 hrs 
post infection and subjected to qPCR or plaque assay(C) to quantify the viral 
loads. Results are expressed as representative mean±S.D from three 







To verify this data, gain-of-function studies were performed where ANXA1 
was overexpressed in A549 cells using V5-tagged ANXA1 cloned in 
pcDNA3.1 vector.  Figure 3.15 shows that  significantly higher titers were 
observed in ANXA1 overexpressing cells compared to the cells transfected 
with empty vector (EV) both in cells (Figure 3.15A) and supernatant (Figure 
3.15B). The overexpression efficiency is shown by qPCR (Figure 3.15C).  
Overall, this data shows that ANXA1 acts to negatively regulate virus titers 
and plays a role in the early stages of viral infection. To extend our findings 
further, we infected mice with influenza virus and investigated the innate 

























Figure 3.15 ANXA1 overexpressing epithelial cell exhibit higher viral 
titers. 
A549 cells transfected with empty vector or ANXA1 plasmid were infected 
with influenza virus. Cells and supernatant was harvested 24 and 48 hrs post 
infection and subjected to qPCR (A) or plaque assay (B) to quantify the viral 
loads. (C) Overexpression efficiency determining ANXA1 levels is tested by 
qPCR Results are expressed as representative mean±S.D from three 
























3.9.  ANXA1 deficient mice are more protected against Influenza virus 
infection. 
 
To assess the involvement of ANXA1 in Influenza virus induced in vivo, we 
infected WT and ANXA1-/- mice with a lethal dose (500 pfu) of Influenza 
H1N1 PR8 virus intratracheally and weight loss was monitored every day for 
20 days. Weight loss is an indirect method to assess the severity of the disease 
and is a good non-invasive way to determine infection related morbidity. The 
mice start to lose weight about 4 days post infection and the consistently lose 
until day 10. After they have lost 25% of the initial body weight, they were 
sacrificed in accordance with IACUC guidelines. Interestingly, when WT and 
ANXA1-/- mice were compared, it was noted that only 20% of WT mice 
survived while 80% of ANXA1-/- survived. (p=0.0065) (Figure 3.16A), as WT 
mice experienced drastic weight loss which was not observed in the ANXA1-/- 
mice. Mice which lost 25% of body weight were sacrificed by day 10 and the 
remaining mice recovered and reached their initial body weight again by day 
13 (Figure 3.16B). These results indicate a role of ANXA1 in influenza virus 
infection, where the absence of ANXA1 protected mice from the effects of the 
virus.  We next determined the regulation of ANXA1 post infection and 
characterized the infection on the basis of viral titers, cytokine responses, 





Figure 3.16 ANXA1 defecient mice are protected against influenza A PR8 
infection when challenged with 500pfu dose. 
(A) 10 mice /grp were infected intratracheally with 500pfu and the weight loss 
was monitored over 20days. Mice were sacrificed when they lost 25% of their 
body weight. Figure (B) represents the weight loss when infected with 500pfu. 
The data is representative of two independent experiments, n=10 /grp.  Data is 







3.10.  ANXA1 is a virus inducible protein and is cleaved upon infection 
 
To elucidate the mechanism on how ANXA1 exerts its effects, we first 
determined if ANXA1 is regulated in vivo in the lungs upon infection as 
observed in the lung epithelial cells, we harvested the lungs from  WT mice 1, 
3 and 5 days post infection and qPCR (Figure 3.17A) and western blot (Figure 
3.17B) was performed for ANXA1 expression. ANXA1 was observed to be 
upregulated both transcriptionally and translationally post infection. RNA 
levels rapidly increase by two folds one day p.i. and decrease subsequently. 
Increase in protein levels followed soon after and ANXA1 upregulation and 
cleavage was evident 3 days p.i.  These results are similar to the ones obtained 
by Katoh et. al where ANXA1 levels were upregulated in porcine monocytes 
infected with swine flu virus (Katoh, 2000). ANXA1 is cleaved at its N-
terminus by serine proteases and the current view in the field is that the 33kDa 
cleaved form is pro-inflammatory (Vong et al., 2007; Williams, et al., 2010). 
This cleaved form is present in high amounts in broncheo-alveolar lavage 
(BAL) from cystic fibrosis patients and correlates with amount of neutrophil 
infiltration and neutophil elastase (Tsao, Meyer, Chen, Rosenthal, & Hu, 
1998). However, in the influenza infection both the full length and cleaved 










Figure 3.17 ANXA1 is a virus inducible protein and is cleaved upon 
infection 
Levels of ANXA1 are increased in lungs of the infected mice as determined by 
(A) qPCR (B) western blot 1, 3 and 5 days post infection. Data in (A) is 
expressed as mean ± SEM from three independent experiments and analysed 
using student’s t test **p<0.01. (B) Tubulin is used as loading control.(C) 




3.11. Viral loads in ANXA1 deficient mice are lower compared to the WT 
mice 
 
To determine the virus load in the lungs of infected mice, mice were sacrificed 
5 days p.i and lungs were harvested. Lungs were then either homogenized for 
the plaque assay on MDCK cells (Figure 3.18A) or stored in RNA later for 
total RNA isolation. qPCR was performed with the isolated RNA and the 
amount of viral M (Figure 3.18B) and NS1 (Figure 3.18C) genes was 
quantified. Interestingly, we observed that the virus titers in the lungs of 
ANXA1-/- mice were lower compared to that of the WT mice by at least one 
log. This data complements our in vitro data where we observe less virus titers 
upon ANXA1 knock down and higher titers upon overexpression. The lower 
viral loads in the ANXA1-/- mice can be attributed either to defective 
replication and propagation or to the efficient clearance of the virus. To address 
the virus clearance, levels of pro-inflammatory cytokines and Type I 
interferons were determined locally in the BAL. The results are described in 




Figure 3.18 ANXA1 deficient mice exhibit lower viral titers in lungs. 
Viral load in the lungs of infected mice was measured using (A) plaque assay 
and qPCR (B) M1 (C) NS1 genes 5 days post infection. Data is representative 
of two independent experiments where each experiment had at least 5 









3.12.  The cytokine and type-I interferon responses are similar in WT and 
ANXA1-/- mice. 
 
Influenza virus up regulates several pro and anti-inflammatory cytokines along 
with type I interferons. Macrophages and dendritic cells are the major 
producers of these. Previously, in our in vitro assays we observed opposite 
trends in cytokine production between WT and ANXA1-/- BMMOs and 
BMDCs. when treated with R848.  Influenza infection is mainly localized to 
lungs in the early stages therefore the maximum amount of cytokines can be 
detected in the BAL. To determine the kinetics of production of these 
cytokines, BAL from mice 1, 3 and 7 days post infection was harvested and 
subjected it to ELISA. We chose a comprehensive panel to include most of the 
important cytokines and divded it into three sections pro-inflammatory (IL-6, 
IL-12, TNF-α, IL-1β), anti-inflammtory (IL-10 and TGF-β) and Type I/II 
interferons (IFNα, IFNβ and IFNγ). Levels of IL-6 increased in a time 
dependent manner from day 1 to 7 for WT and ANXA1-/- mice whereas IL-12, 
TNF-α and IL-1β peaked at day 1 or 3 and subsided by day 7. The anti-
inflammatory cytokines IL-10 and TGF-β were also at their maximum levels 3 
days post-infection and dropped down to the basal levels by day 7. IFN α/β 
peaked at day 3 and IFNγ increased in a time dependent manner until day 7 p.i 
(Figure 3.19). However, no significant differences were observed between WT 















Figure 3.19 Cytokine levels are similar in both wild type and ANXA1 
deficient mice. 
Cytkokine analysis was performed on the  bronchioalveolar lavage obtained 
from  mice 1,3,and 7 days post infection  by ELISA. Figures A-D represent 
pro-inflammatory cytokines, E-F anti-inflammatory cytokines and G-I  type I 
& II interferons. Data is representative of two independent experiments where 













3.13.  ANXA1-/- mice display higher leukocyte infiltration in the BAL fluid 
 
To further characterize the inflammatory cell milieu that is present in the 
airways during influenza infection, differential cell counts were performed 
using multicolour flow cytometry.  
Cells were differentiated on the basis of following cell surface markers. 
Eosinophils - CD45+ SigF+ Ly6Glow/- F4/80- CD11clow
Neutrophils (PMNs) - CD45+ SigF-  Ly6G+
Monocytes - CD45+ SigF- Ly6G- F4/80+ CD14+
Alveolar macrophages – CD45+ Sig F+ Ly6Gint CD11c+ F480+
Lymphocytes – CD45+ SigF- Ly6G- F4/80- CD14- CD3/CD19+ 
 
Significant rise in the total number of cells retrieved in the BALF of influenza-
treated mice was observed as compared to the naive mice, and were higher in 
ANXA1-/- compared to the WT (Figure 3.20B). The early innate immune 
response was marked by significant increases in neutrophils and alveolar 
macrophages (Figure 3.21 A&B) by day 3 pi and lowered by day 7 p.i.. 
Monocytic cells (Figure 3.21C) were significantly elevated between days 3 
and 7 p.i. A marked increase was observed in lymphocytes (Figure 3.21D) at 
day 7 p.i. Monocytes, neutrophils and lymphocytes were observed to be 
significantly higher in ANXA1-/- mice compared to the WT mice. Eosinophils 
were not observed until day 7 p.i., and numbers were not significantly different 






Figure 3.20 Gating Strategy for cell counts in BAL. 
(A) Cells present in BAL were stained with various cell surface markers and 
categorised into eosinophils, neutrophils, alveolar macrophages, lymphocytes 
and monocytes.(B) Cells obtained in BAL were pelleted and counted using 
trypan blue. Data is representative of 2 independent experiments n=5/group/time 























Figure 3.21 Influenza infection leads to higher cellular infiltration in the 
BAL from ANXA1-/- mice. 
Cells obtained in BAL were stained and characterized 3 and 7 days p.i.using flow 
cytometry. Data is representative of 2 independent experiments n=5/group/time point. 










3.14.  ANXA1-/- mice display higher lung inflammation  
 
Having established the increased infiltrates in the lungs by flow cytometry, we 
further performed histopathology using H&E staining to visualize the 
infiltration and assess the inflammation. We focused on the large conducting 
airways close to the site of bronchus bifurcation as this is the site of viral 
replication during early infection and provides clear visualisation of the 
bronchial epithelial lining and cellular infiltration into the peribronchial and 
alveolar spaces. In the uninfected lungs the characteristic “honeycomb” 
structure could be observed. The peribronchiolar spaces were free from 
infiltrates and the airways looked clear. By day 5, mild inflammatory cell 
infiltrate was observed in the peribronchiolar compartment and traces of red 
blood cells were also detected in the conducting airways as well as the alveolar 
air spaces, indicative of pulmonary haemorrhage. By day 10, severe 
inflammatory cell infiltrate of the peribronchiolar space with a greater 
magnitude of inflammatory foci was found in the alveolar parenchyma in 
ANXA1-/- mouse lungs while in the WT mouse, the inflammation was still 
mild or moderate and did not extend to the alveolar parenchyma. The 
inflammation was scored from 0-3 using the following criterion by an 
independent blinded pathologist (Figure 3.22). 
0  no inflammation 
1 mild, inflammatory cell infiltrate of the perivascular/peribronchiolar 
compartment; 
 2 moderate, inflammatory cell infiltrate of the 
perivascular/peribronchiolar space with modest extension into the 
alveolar parenchyma; 
 3 severe, inflammatory cell infiltrate of the perivascular/peribronchiolar 




























Figure 3.22 Higher Inflammation is observed in infected lungs. 
(A) Lungs from naïve and mice infected for 5 or 10 days were harvested 
and fixed with 4% paraformaldehyde. Sections were made and slides were 
stained with H&E stain to assess the infiltrationg cells. The blue stained cells 
represent the infiltrate and the arrows point towards them. Slides are 
representative of sections made from 5 different mice/ group (B) Depending on 
the amount of infiltration and extent of spread the slides were scored from 0-3. 











3.15.  ANXA1-/- mice display similar vascular integrity as WT mice  
 
The concentration of serum albumin in BAL fluid reflects vascular integrity in 
pulmonary tissues and permeability of the epithelial lining of the airways and 
was thus measured as an indicator of lung pathology (Figure 3.23). Albumin 
levels increased drastically in the infected mice between days 1-7 p.i, however 




Figure 3.23 Vascular Integrity is compromised upon infection. 
Albumin leakage into BAL was determined by ELISA as a measure of lung 





3.16. WT mice exhibit more apoptosis in their lungs 
 
Caspase 3 activation is essential for viral propagation (Wurzer, et al., 2003) 
and ANXA1 has been shown to be involved in apoptosis (Lim & Pervaiz, 
2007). To determine whether deficiency of ANXA1 effects apoptosis post 
influenza infection we harvested the lungs from naive and three days infected 
mice. Lysates were prepared from small pieces of lungs and western blot for 
cleaved caspase 3 and 7 was performed. Indeed, the levels of cleaved caspases 
observed in the infected WT mice were significantly higher than those of 
ANXA1-/- (Figure 3.24). This data establishes that apoptosis in epithelial cells 
might help virus to replicate to better and make the infection more severe. The 
next step would be to find out the exact role of ANXA1 in the pathway and 
decipher its mechanism. To carry out these experiments we first evaluated 

















Figure 3.24 Wild type infected mice experience more apoptosis. 
(A) Lungs from mice infected with 500pfu H1N1 PR8 were harvested 3 days 
post infection and lysed in RIPA buffer.  Protein obtained was run on a SDS-
PAGE and probed with apoptotic markers. The blot shows samples from 2 
naïve and 2 infected mice.(B) Quantification of Cleaved caspases 3 and 7 with 
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3.17. ANXA1 is required for virus induced apoptosis  
 
Caspase 3/7 activity is the hallmark for apoptosis. To determine influenza 
induced apoptosis and whether there was any difference between WT and 
ANXA1 deficient cells we first derived cells from lungs by digesting them and 
then culturing the single cell suspensions. The cells were infected with 
influenza virus and caspase 3/7 activity was measured. The activity measured 
was low and not much apoptosis was seen. However, we still observed a 2 fold 
difference between the capase 3/7 activity in WT compared knock down cells 
(Figure 3.25A). This might be because the whole lung culture was a mixture of 
epithelial and fibroblast cell population and PR8 virus cannot replicate 
efficiently in fibroblasts (Stewart & Frickey, 1966). Following this, the 
overexpression and knock down studies were carried out in A549 cells. As 
expected influenza virus induced severe apoptosis in A549 cells which resulted 
in a significant increase in caspase activity. Comparing these values between 
WT and ANXA1 silenced cells there was a partial decrease in the ANXA1 
knock down cells (Figure 3.25B) which was reversed by ANXA1 
overexpression (Figure 3.25C). This observation supports our in vivo data 
where higher apoptosis is observed in WT mice and our hypothesis that 






Figure 3.25 ANXA1 is required for virus induced apoptosis. 
(A) Single cell suspension obtained from lung after digestion were cultured and 
infected with Influenza virus. Caspase activity was measured 48hrs p.i. (B) 
ANXA1 was silenced in A549 cells using shRNA and caspase activity was 
measured 48hrs p.i (C) The reversal of phenotype is shown by overexpression 
of ANXA1 48hrs p.i. Data is represented as mean±S.D and is representative of 
three independent experiments. Cntrl represents control siRNA, KD is ANXA1 
siRNA , EV is empty vector and ANXA1-V5 is ANXA1 overexpression 







3.18.  ANXA1 inhibits NF-κB activation during influenza infection  
 
ANXA1 has been shown to interact with NF-κB and inhibit its activation (Z. 
M. Wang et al., 2011; Zhang, Huang, Zhao, & Rigas, 2010). Zhang et. al also 
reported induction of apoptosis with inhibition of NF-κB due to ANXA1. NF-
κB has been reported as a pro-survival gene widely in the literature, therefore 
we hypothesized that inactivation of NF-κB upon infection might lead to 
higher apoptosis and hence higher viral loads. To put our hypothesis to test we 
overexpressed ANXA1 in A549 cells and measured NF-κB promoter activity 
by dual luciferase reporter assay. The cells transfected with empty vector 
displayed a threefold increase in the activity whereas no increase was detected 
in the cells overexpressing ANXA1 (Figure 3.26). A significant difference was 
also observed between the EV and ANXA1 transfected cells after infection, 
thus confirming that NF-κB activity reduced in presence of ANXA1 and results 
in higher apoptosis which may in turn be the cause of higher viral titers 
observed in presence of ANXA1. Overall, our data points towards the role of 












Figure 3.26 NF-κB activity is decreased in presence of ANXA1 upon 
infection. 
EV and V5-tagged ANXA1 were transfected in A549 cells for 36hrs followed 
by infection for 4 hrs. Promoter activity was determined by dual luciferase 
reporter assay. Data is representative of 3 independent experiments, expressed 


















Chapter 4 Discussion  
 
 
4.1. Summary of key findings 
 
This study has established that ANXA1 controls TLR7 signalling in a cell 
specific manner and is a positive regulator of Influenza virus infection, both in 
vivo and in vitro. We show that ANXA1 plays a crucial role in TLR7 
signalling. R848 activated BMMOs from ANXA1-/- mice exhibit low levels 
pro-inflammatory cytokines while BMDCs from these mice produce very high 
levels of pro-inflammatory cytokines compared to their WT controls, 
highlighting the importance of cell-type specificity. B cells from ANXA1-/- 
mice also demonstrate an activated phenotype and proliferate faster compared 
to the WT. TLR7 dependent inflammasome activation is higher in the  
ANXA1-/- cells. We also show that ANXA1-/- mice have a better survival rate 
compared to the WT mice. ANXA1 is a virus inducible protein and its presence 
supports viral propagation. It is upregulated and cleaved upon virus infection. 
Viral titers drop when ANXA1 is knocked out of the system and increase upon 
over expression. Higher cellular infiltration was observed in ANXA1-/- mice 
however, not much difference was seen in terms of cytokines and interferons. 
Lower levels of apoptosis noticed in ANXA1-/- mice and cells, might be 
implicated as the cause for reduced virus loads. Overall, our data establishes 





4.2. Regulation of Cytokines in BMMOs and BMDCs 
 
Previous studies from our lab demonstrate that ANXA1 plays a role in TLR3 
signalling by aiding phosphorylation and translocation of  IRF3 to the nucleus 
(Bist, et al., 2013). TLR7 and TLR3 can both recognize influenza virus because 
of the ssRNA and dsRNA intermediate it forms during replication. However, 
TLR3 has detrimental contributions in influenza pathogenesis (Le Goffic et al., 
2006) whereas TLR7 agonists are seen as a promising antivirals (Lund et al., 
2004), and when we started this project, no other study had reported the role of 
ANXA1 on TLR7 signalling. Therefore we focused our work on the role of 
ANXA1 in TLR7 signalling.   In this study R848, a TLR7 agonist was used to 
determine the cytokine responses in BMMOs and BMDCs. R848 was observed 
to be the most potent out of all TLR7 agonists we used due to the chemical 
modifications in its structure. It is derived from R837 (Burns, Ferbel, Tomai, 
Miller, & Gaspari, 2000). R848 stimulates the Myd88 dependent pathway to 
produce downstream cytokines (Hemmi et al., 2002) . In the case of BMMOs 
we observed that cytokines like IL-6 and IL-12p40 are downregulated both at 
RNA and protein level. Stimulation with LPS which activates both MyD88 and 
TRIF, abrogated production of TRIF dependent cytokines in BMMOs  but had 
no effect on IL-6 production (Bist, et al., 2013). However, TLR7 dependant 
cytokine production is reversed in DCs where IL-6 and IL-12p40 production 
was observed to be higher in ANXA1-/- cells. Our data is consistent with Weyd 
et. al who showed recently that ANXA1 suppresses DC activation upon R848 
treatment (Weyd, et al., 2013).  This inhibition in cytokine production by 
ANXA1 was observed previously in fibroblasts and peritoneal macrophages, 
where ANXA1 negatively regulated IL-6 and TNF-α production by regulation 
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of p38 MAPK and MAPK phosphatase-1 (Y. H. Yang, et al., 2009; Y. H. 
Yang, et al., 2006). This shows ANXA1 regulates the signalling pathways in a 
cell specific manner. ANXA1 displayed cell specific effects with respect to 
proliferation. In RAW264.7  cells, a macrophage cell line, ANXA1 inhibited 
proliferation while it induced proliferation in hepatocytes (Lim & Pervaiz, 
2007). ANXA1 has been shown to interact with NF-κB, the master regulator of 
pro-inflammatory cytokines and it is essential for IRF-3 activation and 
translocation to the nucleus (Bist, et al., 2013; Zhang, et al., 2010). DNA 
binding of NF-κB subunit p65 is reduced in presence of ANXA1 (Weyd, et al., 
2013). Therefore, regulation of TLR7 pathways by ANXA1 through 
differential interference with NF-κB and IRF-3 activation might be the reason 
behind this selective production of cytokines in different cell types. This cell 
specificity might also contribute to the reason of why we do not observe any 
differences in the cytokine levels in vivo. Another reason could be the different 
expression of the receptor levels of TLR7 in both macrophages and DCs, but in 
our study, we found that the levels were similar.  We also observed differences 
TLR7 dependent IL-1β production through the activation of inflammasome but 
no differences were observed in IL-1β in vivo. This might be due to the 
redundancy of IL-1β production pathways i.e the involvement of caspase-1 
independent pathways that do not require TLR signalling (Mayer-Barber et al., 
2010) .  
We next infected BMMOs and BMDCs with influenza virus and evaluated the 
pro-inflammatory cytokine response. Levels of IL-6, IL-12 and TNFα in 
BMMOs were negligible while DCs produced intermediate levels compared to 
what we observed with R848. Infection of both BMMOs and BMDCs is 
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abortive, i.e. these cells can be infected, though at a very low percentage but 
virus cannot replicate inside (Ioannidis, Verity, Crawford, Rockman, & Brown, 
2012; Wells, Albrecht, Daniel, & Ennis, 1978).  Differential cytokine 
production between BMMOs and BMDCs has also been observed upon 
mycobacterium (Hickman, Chan, & Salgame, 2002) and salmonella infections 
(Yrlid, Svensson, Johansson, & Wick, 2000).  
There are a variety of other factors which can regulate infection such as type of 
DCs or macrophages.  Alveolar macrophages are infected better compared to 
peritoneal macrophages (B. M. Hartmann et al., 2013; Lee, Dutry, & Peiris, 
2012).  In addition, the type of influenza virus strain can predict infectivity of 
abortive cells.  Highly pathogenic strains like H5N1 infects almost all cell 
types as compared to H1N1 (Chan, Leung, Nicholls, Peiris, & Chan, 2012) and 
the host, (ferrets or human) blood cells are better compared to mouse cells (van 
Riel et al., 2007) . The mechanism of infection is not well understood but it 
may be through phagocytosis. However, the question that remains to be 
answered is why DCs are more susceptible than macrophages. The 
conventional sialic acid receptor is absent in both cell types and alternate 
receptors such as C-type lectin receptors namely macrophage mannose receptor 
(MMR), macrophage galactose-type lectin (MGL) etc. have been shown to aid 
influenza virus entry (Londrigan, Tate, Brooks, & Reading, 2012; Upham, 
Pickett, Irimura, Anders, & Reading, 2010) Apart from these two receptors, 
DCs have been shown to express a few more receptors like DCIR, Langerin, 
DC-SIGN, Dectin-1 and Dectin-2 (Denda-Nagai, Kubota, Tsuiji, Kamata, & 
Irimura, 2002). Presence of these receptors that aid phagocytosis and 
endocytosis might provide DCs an edge over the macrophages, possibly 
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leading to more cytokine production after infection. Another reason might be 
the presence of Mx gene that confers resistance to influenza infection  is very 
highly expressed in macrophages (Arnheiter & Haller, 1983; Horisberger, 
Staeheli, & Haller, 1983; Staeheli, Haller, Boll, Lindenmann, & Weissmann, 
1986; Staeheli et al., 1986). 
 
4.3. Enhanced B cell proliferation in ANXA1-/- cells 
 
B lymphocytes play an important role in both adaptive and innate immunity. 
TLR agonists like LPS and immiquinods activates B cells and stimulates 
proliferation and IgM secretion (Yazawa et al., 2003). Exogenous 
physiological signals leading to B-cell activation have been classified as 
“signal 1,” the stimulation of the B-cell receptor (BCR) by antigen binding; 
“signal 2,” the stimulation of CD40 by the CD40 ligand molecule, expressed 
on activated helper T cells; and “signal 3,” the stimulation of Toll-like 
receptors (TLRs) by microbial components or their mimics. All three signals 
together are required for maximal proliferation of naive B cells (Ruprecht & 
Lanzavecchia, 2006). However, stimulation with TLR ligands alone, for 
example, CpG DNA, is sufficient to cause transient B-cell activation, including 
proliferation and induction of immune effector molecules such as CD86, a T-
cell-costimulatory molecule (G. Hartmann & Krieg, 2000). B cells express 
several TLRs on their surface mainly TLRs 1,6,7,9, 10 and RP-105 and main 
TLR induced responses include proliferation, activation and plasma cell 
differentiation (Bohnhorst et al., 2006). R848 induced proliferation is similar to 
the effects brought about by CD40-CD40L interactions (Bishop, et al., 2000) . 
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We observed that R848 activates and induces proliferation in both WT and 
ANXA1-/- cells however, both these are significantly higher in the ANXA1-/- 
cells. On the other hand, effect of TLR ligands on T cells is controversial. Most 
studies indicate that T cells express no or very low expression of only some 
TLRs such as TLR6, TLR8 and TLR2 (Rich et. al. 2005) while others have 
demonstrated direct effects of TLR on T cell with TLR9 ligands like CpG. 
However, in our hands we do not observe any T cell proliferation upon 
treatment with R848 (data not shown).  
Higher phosphorylation in Akt, an important player in cell survival was 
observed which might contribute to the higher proliferation in ANXA1-/- cells. 
Akt has not been shown to be regulated by ANXA1 before but it is known to 
regulate other cell proliferation players such as MAPKs ERK1/2 and p38 
(Alldridge & Bryant, 2003; Y. H. Yang, et al., 2006). TLRs play a role in the 
early stages of B cell response such as induction of proliferation and fine 
tuning of IgG class switching, but are not sufficient alone in the maturation and 
secretion of antibodies. Help from other factors like IFNα is required for proper 
response. As our in vivo data with influenza virus indicates that there are no 
significant differences in the production of IFNα, we might expect with all 
other factors remaining constant, proliferation induced in absence of ANXA1 
might contribute to a better humoral response. In our previous publication with 
respect to asthma we did observe higher allergen-specific and total IgE, IgG2a 
and IgG2b levels in ANXA1-/- mice (Ng et al., 2011). Influenza specific serum 
IgM levels usually peak after 8 days p.i and IgG even later (Wolf et al., 2011). 
However, most of our experiments do not exceed day 7 because that is the time 
when most mice lose 25% of the body weight and have to be sacrificed. 
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Therefore, we could not quantify antibody production in this set of 
experiments.  However we predict that the antibody production will be higher 
in the serum of ANXA1-/- mice.  
 
4.4. Regulation of ANXA1 during influenza virus infection 
 
Expression of ANXA1 is detected in various cell types like neutrophils (Oliani, 
Paul-Clark, Christian, Flower, & Perretti, 2001), monocytes (Harricane, et al., 
1996), mast cells (Oliani, Christian, Manston, Flower, & Perretti, 2000) and 
epithelial cells (Sena et al., 2006). The levels of the protein increase during 
some inflammatory reactions however the exact reason of this upregulation is 
still unknown. We have observed this increase in the lungs of influenza 
infected mice.  This is in line with previous studies where increased levels of 
ANXA1 was observed in porcine monocytes infected with swine flu virus 
(Katoh, 2000). However, this increase in ANXA1 is not specific to viral 
infections but also has been shown in bacterial infections. Previously an 
increase has been observed in ocular taxoplasmosis (Mimura, Tedesco, 
Calabrese, Gil, & Oliani, 2012) and LPS induced endotoxemia (Damazo, et al., 
2005). These observations indicate towards ANXA1 being a virus-inducible or 
infection-inducible protein. We have shown in our study that this increase is 
due to the enhanced promoter activity of ANXA1. 
We also observed that ANXA1 is cleaved into a 34kDa fragment and a small 
3kDa fragment upon infection. Similar cleavage has also been shown when 
Raw 264.7 cells were treated with LPS and poly (I:C) (data not shown) and  in 
tuberculosis infection (Gan, et al., 2008). This cleavage is thought be a result of 
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proteolytic action of enzymes such as elastase or calpain and cleaves at the N-
terminal of the protein (Rescher, Goebeler, Wilbers, & Gerke, 2006; Williams, 
et al., 2010). The cleaved form is observed at day 3 but absent at day 5. This 
might be because the infiltration of neutrophils is highest at day 3 and they 
secrete enzymes like elastases which as described earlier can cleave ANXA1. 
Most studies have been done in macrophages or neutrophils; however this 
phenomenon has not been previously tested in epithelial cells, and we are the 
first to show this.  The cleaved ANXA1 is implicated to play a role in apoptosis 
or is observed to have pro-inflammatory activities against the previous 
conventions that ANXA1 is anti-inflammatory (Williams, et al., 2010). WT 
cells exhibit higher levels of apoptosis which support the experiments by Peng 
et al. where cyclohexamide treatment increases levels of cleaved ANXA1 
which is abolished on treatment with calpain inhibitors. 
WT and ANXA1-/- mice have similar cytokine levels in their BAL after 
infection even though lower levels may be expected in WT due to the presence 
of anti-inflammatory ANXA1.  However, since ANXA1 is cleaved upon 
infection, we can reason that the pro-inflammatory effects may balance the 
anti-inflammatory effects.  
 
4.5. ANXA1 positively regulates virus propagation 
 
Our data clearly shows that ANXA1 plays a crucial role in virus propagation. 
We have shown in vivo and in vitro that presence of ANXA1 leads to higher 
virus titers. By carrying out both loss and gain of function studies, the positive 
correlation between ANXA1 and viral titers were observed. To make our 
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assays more sensitive we used both qPCR and plaque assays. Plaque assay 
estimates the number of live virions capable of producing cytopathic effects in 
the MDCK cell monolayers. Though the plaque assay is a more direct way of 
quantifying the virions released in the supernatant, it is less sensitive than 
qPCR. Real time PCR detects every single copy of viral RNA whereas the 
plaque assay will detect a plaque forming unit that might contain any number 
of viruses. Viral propagation can be divided into three main processes entry, 
replication and budding. By assessing viral titers in the cells infected by the 
virus, we confirmed that ANXA1 plays a role in the early stages of propagation 
i.e entry or replication, and these lower viral titers are also reflected after 
budding into the supernatant. Two recent reports have been published on 
ANXA6 and influenza. Both show a negative correlation between ANXA6 and 
influenza virus titers. The mechanisms of regulation revealed by the two papers 
are however very different. Musinol et. al show that viral replication and 
propagation is inhibited in ANXA-6 deficient cells due to disturbance in 
cholesterol levels in the late endosomes (Musiol et al., 2013) whereas the Ma 
et. al demonstrated that the early steps in viral life cycle are not affected 
ANXA-6 disrupts the budding process. Our mechanism of ANXA1 on 
apoptosis is different from the two processes mentioned but it would be 
interesting to also study the involvement of ANXA1 in cholesterol balancing or 
interaction of ANXA1 with viral proteins. 
 




We observed a strong phenotype in the survival of mice when we infected 
them with a lethal dose of flu virus where ANXA1-/- mice have better survival 
rates. Influenza virus replicates in epithelial cells due to which they produce 
chemokines and cytokines and recruit the mononuclear cell population to the 
site of infection. The first question that was to be answered was whether it is 
the cytokine storm that is the reason for extensive weight loss in WT mice.  
Since ANXA1 is an immunomodulatory molecule it would be quite unlikely 
that WT mice have higher levels compared to ANXA1-/- but we still needed to 
investigate it. To our surprise, the levels of cytokines in both WT and   
ANXA1-/- were similar and no significant difference was observed in pro or 
anti-inflammatory cytokines and type I interferons. The kinetics of production 
of these cytokines over 7 days was also similar in WT and ANXA1-/- mice. 
Cytokines and chemokines are the mediators which cause the clinical signs 
related to the infection. IL-1, IL-6 and IL-12 have been correlated with the 
symptom pathogenesis during acute influenza (Kaiser, Fritz, Straus, Gubareva, 
& Hayden, 2001; Kostense et al., 1998; Schmitz, Kurrer, Bachmann, & Kopf, 
2005). The viral titers however may not negatively correspond to the cytokines. 
In our study the cytokine levels are similar but viral load in ANXA1-/- is lower 
and another study shows lower cytokine levels in TLR3-/- mice but higher viral 
loads compared to the WT (Le Goffic, et al., 2006). Lesser viral loads in the 
early phases of infection and no differences in the cytokines led us to 
hypothesize that influenza virus is unable to propagate efficiently in ANXA1-/-  
mice rather than it being a case of efficient clearance.  The lung damage as 
determined by Albumin ELISA was also similar in both WT and ANXA1-/- .  
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Accumulation of inflammatory cell infiltrate is another hallmark of influenza 
virus infection. Lymphocytes mainly CD8+ T cells infiltrate from the lymph 
nodes later in the infection and APCs infiltrate earlier which provide 
costimulatory signals for the activation of effector CD8+ cells following which 
effector CD8+ T cells cause cytolysis of infected epithelial cells (Hufford et al., 
2012). We found higher numbers of infiltrating lymphocytes, monocytes and 
neutrophils in ANXA1-/- mice.  Other studies related to lung fibrosis (Damazo 
et al., 2011), intestinal ischemia (Guido, Zanatelli, Tavares-de-Lima, Oliani, & 
Damazo, 2013) and zymosan induced inflammation(Getting, Flower, & 
Perretti, 1997) also observe higher recruitment of leukocytes in absence of 
ANXA1. Inhibition of leukocyte migration is one of the ways by which 
ANXA1 brings about its anti-inflammatory effects (Getting, et al., 1997; Lim, 
Solito, Russo-Marie, Flower, & Perretti, 1998) . The mechanism of this is 
proposed to be the inhibition of transmigration of cells through the 
endothelium due to the externalization of ANXA1 on the surface of adherent 
cells (Perretti et al., 1996). The same levels of cytokines in BAL and more 
cellular infiltration might point towards less cytokine being produced per cell 
in the ANXA1-/- mice. The human N-formyl peptide receptor (FPR) is a key 
modulator of chemotaxis directing granulocytes toward sites of infections. 
Since ANXA1 is a ligand for all FPR receptors, it desensitizes the cells towards 
subsequent activation from other stimuli and  the inhibits transmigration of 
leukocytes (Ernst, et al., 2004).  
Our data suggests that ANXA1 affects viral propagation but the mechanism is 
not clear. There might be few mechanisms i) ANXA1, like ANXA6 might 
interact with M2 which is an ion channel protein (Ma, et al., 2012) , and 
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interfere with the uncoating of the viral envelope ii) ANXA1 might induce 
dephosphorylation of BAD upon infection and allow its transportation to the 
nucleus for induction of apoptosis through intrinsic pathway as influenza virus 
has been shown to induce apoptosis via BAD mediated mitochondria 
dysregulation (Tran, Cortens, Du, Wilkins, & Coombs, 2013) iii) ANXA1 
interferes with RIP-1 poly- ubiquitination by E3 ligase (unpublished data) and 
this might lead to inhibition of NF-κB signalling and hence enhancing 
apoptosis.  
Apoptosis plays an important role in viral propagation (Wurzer, et al., 2003) 
and ANXA1 is a pro-apoptotic molecule (Lim & Pervaiz, 2007; Solito, et al., 
2001; Solito, Kamal, et al., 2003) which might help the virus in its better 
propagation and hence lower survival of the mice. In case of complex disease 
like Influenza, a combination of multitude of factors determines survival out of 
which one might be apoptosis.  Our results indeed show that higher apoptosis 




Figure 4.1 Putative mechanism for ANXA1 action upon infection 
(i) ANXA1 might interact with M2 protein and interfere with the uncoating of 
the viral envelope ii) ANXA1 might induce dephophorylation of BAD upon 
infection and allow its transportation to the nucleus for induction of apoptosis 
through mitochondria iii) ANXA1 interferes with RIP-1 poly-ubiquitination 








4.7. Inhibition of NF-κB in ANXA1 overexpressing cells 
  
Suppression of NF-κB by ANXA1 has been shown previously in cancer studies 
(Ouyang et al., 2012; Zhang, et al., 2010). Here, we also observe inhibition of 
NF-κB activity upon ANXA1 overexpression. NF-κB inhibits TNF-α induced 
apoptosis(Van Antwerp, Martin, Kafri, Green, & Verma, 1996) and Curcumin, 
an anti-cancer drug induces apoptosis by inhibiting NF-κB (Shishodia, Amin, 
Lai, & Aggarwal, 2005). These and many other evidences indicate that NF-κB 
is a pro-survival gene and its inhibition leads to higher degree of apoptosis. As 
stated earlier apoptosis is essential for viral propagation, and its inhibition 
might interfere with the propagation. However, a few studies reveal the need of 
NF-κB activation in the propagation (Ehrhardt et al., 2013; Wurzer, et al., 
2004). As discussed before, apoptosis is inhibited in the early stages of 
infection and induced in the later stages and NF-κB activation is also in phases 
therefore, further time dependant experiments need to be conducted to answer 
this discrepancy. 
 
4.8. Limitations of the Study 
 
There are a few limitations to this work. The first is the virus dose. We observe 
the protective phenotype only at 500pfu and no significant difference was 
observed at 750pfu (data not shown). This dose however may or may not be 
physiological. Also we do not have the range where absence of ANXA1 can 
provide the protective effect. The second limitation is the strain of the mice. 
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C57/B6 mice are the best models to study influenza since Balb/c mice show 
some resistance to the infection and high doses of virus are required to infect 
them. A third limitation would be the use of only one virus strain H1N1 PR8. 
Other strains like H3N2 or HIN1 WSN/33 could be used.   
 
4.9. Clinical Significance 
 
According to our findings, ANXA1 deficiency has proven to be beneficial for 
the hosts. By restricting the production of progeny virions it helps in the 
containment of the disease and decreases morbidity. Influenza is a one of the 
major threats today. Due to past pandemics and their deadly potential to kill 
millions of people constant surveillance and monitoring is done by health 
organizations throughout the world and new vaccines are generated every 6 
months based on circulating strains. Vaccines are the most effective preventive 
measure against influenza but due to the vast effects of ANXA1 on so cellular 
functions it cannot be a component of the vaccine itself. ANXA1 is a 
glucocorticoid inducible protein and brings about their anti-inflammatory 
effects. Based on this, N-terminal ANXA1 peptides based therapies are being 
tested in mice and rats for ailments like colitis, ischaemic injury, allergic 
inflammation etc. However, no therapies targeting ANXA1 and lowering its 
expression have been studied yet. For the first time detrimental effects of 
ANXA1 expression have been shown with respect to infectious disease. A few 
possibilities that can possibly be tested would be to administer anti-ANXA1 
antibodies or FPR inhibitors along with antivirals to block ANXA1 and in turn 
control viral loads. 
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4.10. Future Directions  
 
This study has established that ANXA1 plays an important role in influenza 
virus pathogenesis and acts as a positive regulator. However, there are a few 
questions that remain to be solved. 
The lower viral titers have been associated with lower apoptosis in absence of 
ANXA1. The executioner caspases have been shown to be affected in ANXA1 
deficient cells. These caspases are common for both extrinsic and intrinsic 
pathways but it is yet to be determined which apoptotic pathway 
(mitochondrial/intrinsic or receptor mediated/extrinsic) involves ANXA1 upon 
infection. The first report that established caspase 3 activation being necessary 
for viral propagation (Wurzer, et al., 2003) have linked the vRNP transport 
from nucleus to cytoplasm, to apoptotic signalling. In this respect it will be 
interesting to observe the movements of ANXA1 in the cell upon infection and 
its interaction with vRNP if any. 
Ma et. al  have shown that human Annexin A6 interacts with the M2 protein of 
the virus, however the functional significance of this interaction is not 
determined yet. Annexins possess a high structural and sequence homology 
except for the N-terminal region. ANXA1 might also interact with M2 or other 
proteins like NS1 and PB2-F2, which are known to induce apoptosis upon 
infection.  
As mentioned earlier ANXA1 has various domains, the C-terminal region is 
conserved while the N-teminal is the unique domain for all annexins. C-
terminal interactions with TBK-1 help ANXA1 to execute its role in TRIF 
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dependent signalling (Bist, et al., 2013). Different N and C terminal mutants 
can be used to detect the domains important for regulating viral pathogenesis. 
ANXA1 on the surface of apoptotic cells suppresses CD8+ T cell immunity by 
preventing DC activation (Weyd, et al., 2013). ANXA1 deficiency in CD4+ T 
cells also allows for exacerbation of T cell dependent immune responses (Y. H. 
Yang et al., 2013). ANXA1 has also been described as the molecular tuner for 
TCR signalling (D’Acquisto, et al.,2007). To find the mechanism of better 
survival of ANXA1 deficient mice we mainly concentrated on the innate 
immune pathways however, considering the above mentioned observations a 
few experiments on adaptive immune cells might provide useful insights into 
the mechanism governing survival. 
4.11. Conclusion 
 
This study has established that ANXA1 plays an important role in TLR7 
signalling and Influenza virus pathogenesis. The novel findings include the cell 
specific role of ANXA1 in innate immune cells upon activation with TLR7 
ligand R848 and its deficiency provides protection against influenza virus in 
mice. ANXA1 interferes with the viral propagation in the early stages of 
infection. The innate immune responses mounted against influenza virus are 
similar in WT and ANXA1-/- mice. Higher apoptosis in the epithelial cells, the 
hosts for virus infection, leads to higher viral loads and morbidity in WT mice. 
Clinically, it will be challenging to target ANXA1 because of its various roles 
in cell function maintenance. Current therapies involve administration of 
ANXA1 in the form of recombinant protein or peptide but lowering its 
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